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Readmission Data Capture Sheet 
                                                                       Patient code: 
Please tick () the appropriate box and fill in not applicable (n/a) if not relevant. 
                          Hospital:  
 
Panorama Medi-Clinic  
Louis Leipoldt Medi-Clinic  
Tygerberg  
Karl Bremer  
    
Admission Date    
Vital Signs    Adm    D/C 
Discharge Date  Pulse   
ICU admission Yes/No Respiratory Rate   
Reason for admission  Temperature   
Pneumonia  Blood pressure   
Dyspnoea     
Bronchospasm     
Unspecified infection     
Increase in sputum 
production 
 Lung Function   
Deterioration in respiratory 
symptoms 
 FEVı   
Deterioration in mobility  
FVC   
New Arrhythmias  
FEVı/FVC   
Medical condition  Blood Gasses   
Stroke  PaCO2  
Cor Pulmonale  PaO2  
Congestive cardiac failure  pH  
Pulmonary embolism  Oxygen Saturation  
Hypertension  Walking:           Yes /No 
Ischaemic Heart Disease  Walking with 
assistance 
Yes /No 
Diabetes Mellitus  
O2 dependant in 
hospital  
Yes /No 
Cancer  Home O2 Yes/No 
Tuberculosis (TB)    
Post TB bronchiectasis    
Smoking? If yes, how 
many years? 
Yes/ No Ex-smoker Yes/No 
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Medication Data Capture Sheet 
 
Patient code: 
                                                  Please tick () the appropriate box  
                                       
                                                  Hospital: 
Panorama Medi-Clinic  
Louis Leipoldt Medi-Clinic  
Tygerberg  
Karl Bremer  
 
Indicate medication by individual name 
Date 
Bronchodilators  Theophylline/ 
Aminophylline 
  Cortico 
steriods  
Antibiotics Mucolytic 
Agents 
Other: 
HPT/ 
Cardiac 
meds 
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ABSTRACT  
 
Acute exacerbation is an important event of COPD as it causes significant disability and 
mortality. Especially repeated hospitalisation of patients with acute exacerbation has been 
associated with reduce quality of life and excessive hospitalisation cost. Chronic Obstructive 
Pulmonary Disease causes significant functional limitations that translate into enormous 
economic and societal burden.  
 
Study Aim: To describe the profile and selected outcomes of Chronic Obstructive Pulmonary 
Disease (COPD) patients admitted with acute exacerbation to hospitals in the northern 
suburbs of the Western Cape.  
 
Study design: A multicenter retrospective descriptive single subject design was used.  
 
Method: Patients admitted with the diagnosis of COPD with acute exacerbation in the time 
period 01June 2004-01June 2005 were followed up retrospectively for a period of 12 months. 
The demographics, medical condition on admission and past presentation of acute 
exacerbation, length of stay in hospital and the number of readmissions for acute 
exacerbation in the 12 month period were collected and recorded on a self designed data 
capture sheet. 
 
Results: One hundred and seventy eight patients were admitted with acute exacerbation at 
the three hospitals. The mean age of the patients were 63 (±11.73), more males than females 
(103: 75) were admitted. Subjects spent a mean of 5.67 (±6.55), days in hospital with every 
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admission and admission frequency of up to eight periods were recorded. Of the n=178 
admitted, 56% had one admission and 44% had 2 or more admissions in the study year. This 
resulted in a total of 338 hospital admissions with the 78 subjects responsible for the majority 
of admissions (238) Subjects presenting with two or more co-morbidities had a significantly 
greater risk of multiple re admissions. Subjects with three or more admissions had two or 
more co morbidities (p=0.001), comparatively those with one admission had only one co 
morbidity. Congestive cardiac failure (p=0.01) as well as the lack of Long Term Oxygen 
Therapy p=0.017) were associated with increase risk of three or more admissions.   
 
Conclusion: Patients admitted with acute exacerbation to the hospitals where the study was 
conducted presented with an age ranging from 30-95 years. Patients with 2 or more 
admissions experience up to eight readmissions episodes in the study year. This is a cause of 
concern in respect of the burden of disease on especially the younger economically viable 
South African population. In the current study factors that influenced readmission were the 
presence of two or more co morbid diseases, specifically the presence of congestive cardiac 
failure as well as the lack of LTOT. Interventions including a pulmonary rehabilitation 
programme post discharge should be aimed at decreasing frequency of hospitalisation 
especially in those patients who are a risk of readmission. 
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ABSTRAK 
Verergering van simptome in Kroniese Obstruktiewe Lugweg Siekte (KOLS) is baie belangrik 
as gevolg van die ongeskiktheid en mortalitieit wat dit veroorsaak. Dit veroorsaak 
vermindering in die kwaliteit van lewe en verhoog hospitaal koste verbind met die siekte. Die 
beperkings toe te skrywe aan die Kroniese Obstruktiewe Lugweg Siekte veroorsaak 
ontsettende ekonomiese en sosiale druk.  
 
Doelstelling: Om die profiel en geselekteerde uitkomste van pasiente met Kroniese 
Obstruktiewe Lugweg Siekte toegelaat met verergering in die hospitale van die noordelike 
voorstede van die Wes Kaap te beskryf. 
 
Studie ontwerp: ŉ Multisentrum retrospektiewe beskrywende enkel persoon studie. 
 
Studie metode: Pasiente toegelaat met verergering van Kroniese Obstruktiewe Lugweg 
Siekte in die periode 01Junie 2004-01Junie 2005 was retrospektief opgevolg vir ‘n periode 
van 12-maande. Demografiese data, mediese toestand op toelating en ontslag, lengte van 
hospitaal verblyf en getal toelatings in die 12- maande was gekollekteer en gedokumenteer 
op self ontwerpde vorms.  
 
Resultate: Een-honderd agt en seventig pasiente was toegelaat met verergering by die drie 
hospitale. Die gemiddelde ouderdom van die studie populasie was 63 (±11.73) met meer 
mans as vrouens (103: 75) toegelaat. Die studie populasie het gemiddelde dae van 5.67 
(±6.55), in die hospitaal deurgebring en toelating frekwensie van agt episodes was 
gedokumenteer. Van die n=178 toegelaat was 56% eenkeer toegelaat en 44% het 2 of meer 
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toelatings in die studie jaar gehad. Dit het in 338 hospital toelaatings veroorsaak en 78 van 
die studie populasie verantwoordelik vir die meeste van die toelatings (238). Die groep met 
drie of meer toelatings in die studie jaar het twee of meer siektetoestande (p=0.001) gehad, 
teenorgesteld met die wat net een toelaat was met een siektetoestand. Hart versaaking 
(p=0.01) en die gebrek aan suurstof by die huis (p=0.017) was verbind met meer risiko van 
drie of meer toelating. 
 
Samevatting: Die ouderdoms verskil  was wydbeskrywend van 30-95 jaar van die pasiente 
wat in die studie jaar toegelaat is by die drie hospitale.  Pasiente wat 2 of meer keer toegelaat 
is het tot agt hertoelatings in die studie jaar gehad. Kommerwekkend is die uitwerking van die 
siekte op die jonger werkend populasie in Suid Afrika. In die studie was hertoelating beinvloed 
deur die teenwoordigheid van twee of meer siektetoestande, spesifiek hart versaaking sowel 
as die gebrek aan suurstof by die huis. Intervensies insluitende pulmonale rehabilitasie na 
ontslag se doel moet wees om vermindering van heraaldelike hospitalisasie in hoë risiko 
pasiente vir hospitalisasie. 
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Chapter 1 
 
Introduction 
 
1.1 Introduction to the study 
 
Acute exacerbation remains an important event in the natural history of COPD. Patients 
diagnosed with COPD may experience frequent episodes of acute exacerbations of three or 
more per year. This is more common in individuals with moderate to severe COPD (Burge 
and Wedzicha, 2003). Even though up to half of the exacerbations may be unreported as they 
may not be severe and do not require hospital admission, there are individuals that may be 
subjected to frequent hospitalisation due to recurrent episodes of acute exacerbation (Hunter 
and King, 2001; MacNee, 2003; Seemungal et al., 1998). As result of multiple hospitalisations 
patients may experience a temporary or permanent decrease in function and are there for 
unable to recover to their pre hospitalisation functional status (Seemungal et al., 1998). 
Frequent readmissions remains a cause for concern as it results in increasing physical 
disability, social isolation, escalation of cost in respect of medical expenses and lost income 
as well as being associated with high mortality (MacNee, 2003).  
 
In a developing country such as South Africa health care providers and health care facilities 
are under increasing pressure to provide comprehensive patient management and cost 
effective measures to deal with chronic diseases (Michaud, 2001). Specifically in developing 
countries, the allocation of scarce resources across the medical field are constantly placed 
under strain by large communities that have limited ability, if any, to pay for services 
rendered, especially in the public sector (www.doh.gov.za/mts/reports/cardiosurgery.html, 
http://scholar.sun.ac.za
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accessed 14. 08.2006). This economic burden is reported to increase further due to an 
increase in life expectancies because of improved access to quality health care (Mathers et 
al., 2006). 
 
Pulmonary rehabilitation remains important in the management of COPD as it aims to 
improve the quality of life of the individual affected by the disease (Fan et al., 2006). There is 
high quality evidence that a pulmonary rehabilitation programme can counteract the negative 
effects experienced from multiple admissions due to acute exacerbation of COPD (American 
Thoracic Society (ATS), 1999; Fahy, 2003; Puhan et al., 2005). The rehabilitation programme 
usually comprises of upper and lower extremity exercises and strength training, education, 
behavioural intervention and nutrition (ATS, 1999; Celli, et al., 2004). Documented benefits 
include increased exercise capacity, increase ability to perform activities of daily living, 
decreased episodes of acute exacerbation, a decrease in dyspnoea, a decrease in anxiety 
and depression, and decreased costs associated with hospitalisation (Puhan et al., 2005; 
Reis et al., 2007).  
 
Evidence for the benefits of pulmonary rehabilitation is well known in developed countries 
(Celli et al., 2004; Fan et al., 2004; Reis et al., 2007). While evidence exists in respect of the 
mortality rates of patients suffering from COPD in developing countries like South Africa, data 
concerning the morbidity of the disease in the developing world is less documented 
(Bradshaw et al., 2000; Bradshaw et al., 2002; Norman et al., 2001; Bradshaw and Steyn, 
2001). The MRC report on chronic diseases of lifestyle in South Africa of 1995-2005 
comments only on the prevalence and risk factors of chronic diseases especially self reported 
chronic bronchitis (Ehrlich and Jithoo, 2006). Even the aforementioned report mentions the 
lack of studies of COPD in the general South African population and base the report on 
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studies using self reported diagnosis of chronic bronchitis or COPD documented during the 
1998 South African Demographic and Health Survey.  
 
Data from the 1998 South African Demographic and Health Survey (SADHS) were also used 
by Bradshaw and Steyn (2001) in their report on Poverty and Chronic Diseases in South 
Africa.  The report as well as the SADHS (1998) documented the prevalence of lung disease 
based on the symptoms of chronic bronchitis, asthma and abnormal peak expiratory flow rate 
(PEFR).The other limitation of the SADHS (1998) is that it was conducted prior to the 
implementation of the GOLD guidelines in 2001 that requires the diagnosis of COPD to be 
confirmed by spirometry although in the SADHS mention is made on the limitation of using 
PEFR above spirometry as the latter would be more accurate in determining COPD. Self 
reported diagnoses are problematic as they are based on the patients recall of the diagnosis 
made by a health professional and is not based on objective measures used by a physician 
and could have led to an under reporting of diagnoses involving COPD (SADHS, 1998; Steyn 
et al., 2006). The report by the department of health do not provide information on the profile 
of  COPD patients hospitalised with acute exacerbation or any information on the readmission 
and days spent in hospital as result of acute exacerbation (Steyn et al., 2006). Unfortunately 
no recent health surveys except the 1998 SADHS are available on the website of the 
department of health.  
 
Other factors specifically within the South African context which could potentially impact on 
the profile of the South African COPD patient admitted with acute exacerbation is the high 
prevalence of HIV/AIDS and TB found specifically in the Western Cape (www.who 
Tuberculosis.htm, accessed 17.03.2005). The impact of the two health care systems namely 
the public and private systems providing services to the South African population and 
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differences in admission criteria that may exist amongst the hospitals and influence 
readmission and the length of stay in hospital is also not clear  
 
This lead to the question: What is the profile and selected outcomes of COPD patients 
admitted with acute exacerbation to hospitals in the northern suburbs of the Cape Metropole?   
The aim of the study was there for to describe the demographics of the COPD patient 
hospitalised with acute exacerbation in the Western Cape prior to recommendations 
regarding the implementation of a pulmonary rehabilitation programme. To answer the 
research question a one year retrospective medical folder search were conducted at both the 
public and private hospitals in the Cape Metropole. 
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Chapter 2 
 
Literature Review 
 
2.1 Introduction  
In this chapter the following topics will be addressed:  the current literature and debate on 
Chronic Obstructive Pulmonary Disease (COPD) and acute exacerbation in relation to the 
burden of disease; the definition of COPD, its causes, diagnosis, development and risk 
factors; the definition of acute exacerbation and its current management; and outcomes of 
COPD. Electronic searches were conducted using the databases of Pubmed Central Library, 
Medline and Google search engines. 
 
2.2 Burden of COPD  
Due to the changing population dynamics the increasing influence of tobacco smoke and air 
pollution, specifically in the developing countries, it is expected that the burden of COPD may 
escalate in those countries (Michaud, 2001). This was particularly evident when, in 1990, 
tobacco smoke as a major risk factor for COPD was ranked fourth in the Burden on Disease 
and Injury Attributable to Selected Risk Factors in the World, as established using the 
disability adjusted life year (DALY) instrument (www.goldcopd.com/, accessed 21.12.2007). It 
was preceded only by unsafe sex, poor water supply and sanitation, and malnutrition 
(www.who.int/whr, accessed 02.06.2007). In projections made on the burden of major 
diseases for the year 2002 to 2030 by Mathers et al. (2006) using updated information but 
similar calculations as used in the Global Burden of Disease (GBD) study, they projected a 
continued increase of tobacco-related diseases even in the light of the HIV/AIDS epidemic. 
http://scholar.sun.ac.za
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The DALY system was developed following the Global Burden of Disease study carried out in 
1990 (sponsored by the World Bank) by researchers at Harvard University and the World 
Health Organization (WHO) (Mathers et al., 2006). The DALY system measures the 
difference between the population health and a specific goal. This system makes it possible to 
estimate the burden of major diseases injuries and risk factors. It was initially developed for 
use in eight regions of the world but now most countries, including the United States and 
others, as well as the WHO utilise this system to ascertain the impact of major diseases 
(Michaud et al., 2001; WHO, 2000). The DALY system uses estimates from the 1990 Global 
Burden of Disease (GBD) study, and it may have underestimated the rapid increase of 
infectious diseases, tobacco related illnesses, HIV/AIDS and tuberculosis, especially in sub-
Saharan Africa and the subsequent impact they will have on life expectancy (Mathers et al., 
2006).  
 
In the preliminary estimates of the WHO GBD study of 2000, COPD resulted in the same 
percentage of deaths as HIV/AIDS, which highlights the significant mortality of this disease 
(Pauwels, 2001; WHO, 2000). Current evidence supports the anticipated escalation of the 
prevalence of the disease as well as the expected increasing impact of acute exacerbations 
with regards to the economic burden as well as the progressive disability that accompanies 
COPD (Mannino, 2002; Pauwels, 2001; Sullivan et al., 2000). The disease affects all aspects 
of the patient’s wellbeing and has an extensive impact on patient and family as the disease 
becomes more debilitating over a period of time as the individual ages. It is anticipated, given 
all the existing developments of increase tobacco usage and rapid industrialisation, that by 
the year 2020 COPD will be the third leading cause of death worldwide even in the light of the 
intensive anti-tobacco smoking campaigns (Sullivan et al., 2003). This is especially evident in 
http://scholar.sun.ac.za
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the developing countries due to increase tobacco usage by the countries (Michaud et al., 
2001).  
 
In a prevalence survey conducted in the United States in 1995 it was found that COPD was 
the cause of most deaths of people above 65 years of age, and that an increase in disability 
due to the ageing population as well as an increase in disease prevalence were expected 
(Weiss et al., 2003). In 2004 it remained the fourth leading cause of death in the United 
States, with an estimated 11 million people suffering from COPD and nearly 24 million 
Americans presenting with evidence of impaired lung function (www.lungusa.org/site/pp.asp, 
accessed  17 March 2005; NHLBI, 2006).   
 
The majority of research on COPD and acute exacerbation, their causes and risk factors have 
been studied within the context of first world countries (MacNee, 2003; Sullivan et al., 2000). 
Apart from the mortality rates attributed to COPD no specific information could be identified in 
a developing country such as South Africa regarding the economic and social burden of the 
disease specifically acute exacerbation. Future research is prudent to determine the 
magnitude of this disease in the South African population as this has extensive economical 
and societal implications (Michaud et al., 2001).  
 
2.3  Definition of COPD 
The definition of COPD and the implementation thereof depend on a specific country’s health 
criteria and application of this definition will affect the prevalence statistics of the disease in 
that specific country (Mannino, 2002).  
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The Global Initiative for Chronic Obstructive Lung Disease (GOLD) defines COPD as follows: 
“a disease state characterized by airflow limitation that is not fully reversible. The airflow 
limitation is usually both progressive and associated with an abnormal inflammatory response 
of the lungs to noxious particles or gases." This definition was used by GOLD in their first 
publication in 2001 (GOLD, 2001) but has subsequently changed in the light of new 
developments. In 2006 GOLD defined COPD as follows: “Chronic obstructive pulmonary 
disease (COPD) is a preventable and treatable disease with some significant extrapulmonary 
effects that may contribute to the severity in individual patients. Its pulmonary component is 
characterized by airflow limitation is usually progressive and associated with an abnormal 
inflammatory response of the lung to noxious particles or gases.”  
 
The definition of COPD proposed in the combined document of the American Thoracic 
Society and the European Respiratory Society (ATS/ERS) of 2004 is as follows: “Chronic 
obstructive pulmonary disease (COPD) is a preventable and treatable disease state 
characterised by airflow limitation that is not fully reversible. The airflow limitation is usually 
progressive and is associated with an abnormal inflammatory response of the lungs to 
noxious particles or gases, primarily caused by cigarette smoking. Although COPD affects the 
lungs, it also produces significant systemic consequences.” 
 
2.4  Development of COPD 
COPD is a disease characterised by lung tissue destruction, mucus hypersecretion, 
accelerated degeneration and inflammation due to noxious gasses or particles, resulting in 
emphysema and chronic bronchitis, or both (Altose, 2003; Hunter and King, 2001).  
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COPD usually refers to chronic bronchitis and emphysema and is included under the umbrella 
term of Chronic Lung Disease that includes other conditions such as cystic fibrosis, 
bronchiectasis and asthma. The definition of COPD excludes asthma due to the reversibility 
of pulmonary function deficits (Hunter and King, 2001). However, individuals may present with 
both symptoms of asthma and COPD and therefore it has been proposed that certain patients 
may present with both these diseases (Mannino, 2002). Chronic bronchitis and emphysema 
are both diseases that do not develop or present rapidly but rather have a slow onset and 
patients progressively become more symptomatic and disabled (Mannino, 2002; Weiss et al., 
2003).   
 
Chronic bronchitis is associated with mucous gland hypertrophy and an increase in mucous 
production, resulting in a chronic productive cough and increase in sputum. This condition is 
defined as a productive cough for most days for three months of the year for at least two 
consecutive years, with subsequent exclusion of other causes of lung pathology. In chronic 
bronchitis inflammation results in scarring of the bronchial walls and excessive mucus is 
produced due to extensive irritation (www.lungusa.org/site/apps/s/content.asp, accessed 05 
December 2006). The accumulation of secretions contributes to bacterial infections within the 
airways and eventually obstructs airflow. Chronic bronchitis can affect individuals of all ages 
but is higher in the over-45-year group (Mannino, 2002).  
 
In emphysema, destruction of the alveolar walls and a decrease in structural support of the 
airways causes premature closure during expiration, resulting in hyperinflation. Destruction of 
the alveoli is permanent.  A decrease in the surface area of the alveoli causes inadequate gas 
exchange, resulting in hypoxaemia, with or without hypercapnia and progressive shortness of 
breath (Hunter and King, 2001; Mannino, 2002).  
http://scholar.sun.ac.za
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Over a period these changes within the trachea, bronchi and bronchioles contribute to an 
increase in anatomical dead space and an overall increase in lung capacity, resulting in 
hyperinflation of the lungs and causing the hemi-diaphragms to become depressed. This 
contributes to the clinical presentation of a patient with an elevated clavicle, a barrel-shaped 
chest and defined sternocleidomastoid and abdominal musculature due to increased muscle 
recruitment during respiration. As result of the pathophysiological changes causing ventilation 
and perfusion inequalities and changes in chest wall structure this contributes to breathing 
inefficiency and increased metabolic cost (Hunter and King, 2001; Jones et al., 2003). This 
results in symptoms such as coughing, wheezing, shortness of breath and reduced exercise 
tolerance (Mannino, 2002). 
 
As COPD is a progressive disease with insidious onset, symptoms can vary considerably 
amongst individuals. The presence of symptoms depends on the extent of the exposure to 
risk factors that an individual is subjected to and an individual’s genetic predisposition to 
develop COPD. In their article on COPD, Weiss et al. (2003) consider the impact of childhood 
asthma and allergy on lung development during the growth period as well as the potential to 
affect future development and susceptibility to COPD. Thus, individuals who present with 
respiratory symptoms and a positive childhood history of respiratory complaints such as 
bronchitis and asthma and who engage in activities such as smoking may predispose them to 
develop COPD compared to a non-smoker with the same history. These patients may also 
develop more severe COPD and have an increased risk of acute exacerbations and poorer 
prognoses (Jeffery, 2002). 
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2.5  Causes of COPD and associated risk factors 
There is a complex variety of factors that influence the development of COPD in an individual 
within a first world population: age, genetics, gender, airway responsiveness, allergy, 
smoking, occupational exposure, infections, nutrition and environmental allergens 
(www.goldcopd.com/, accessed 21.12.2007; Mannino, 2002; Weiss et al., 2003). In South 
Africa the increasing prevalence of tuberculosis (TB), exposure to industrial and mining dust,  
and biomass fuel used for cooking by the underprivileged in poorly ventilated houses are all 
recognised as additional causes for the development of COPD (Bateman et al., 2004). 
 
2.5.1  Age 
Historically, the risk of developing chronic lung disease has been associated with older age as 
the diagnosis of COPD is usually made later in life (Bateman et al., 2004; Sullivan et al., 
2003). Older age combined with a strong smoking history increase the risk of developing 
COPD in susceptible individuals. Individuals may initially attribute their deteriorating health to 
growing old and only seek medical attention when symptoms significantly impede their daily 
living activities (Mahler, 2006).  
 
Increasingly, younger individuals are diagnosed with COPD as advances in technology, 
education levels and diagnostic procedures facilitate diagnosis. Socio-economic growth also 
results in changing patterns in society affecting values and norms, and consequently younger 
people are being exposed and the effects of smoking both actively and passively and 
therefore the potential effects of the disease (Bradshaw and Steyn, 2001; Mannino, 2002).  
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2.5.2 Genetic  
Only a relatively small percentage of individuals present with the genetic inherited alpha1 
antitrypsin deficiency, accounting for about 5% of the emphysema statistics in the United 
States, primarily amongst individuals from Northern European descent 
(www.lungusa.org/site/apps/s/content.asp, accessed 05 December 2006). Inherited alpha1 
antitrypsin (AAT) deficiency related emphysema is caused by a deficiency of the protein 
alpha1 antitrypsin, a lung protector released by the liver, and should be considered if non-
smokers younger than 40 years of age are diagnosed with COPD 
(www.lungusa.org/site/pp.asp, accessed  17 March 2005).  
 
The symptoms of AAT deficiency related emphysema may present from the age of 32 to 40 
and smoking greatly increases the severity of emphysema in these individuals. Individuals 
who have a positive family history of emphysema or chronic bronchitis and meet the criteria of 
risk factors for COPD may also have genetic factors influencing their predisposition to 
develop the disease. This, however, is still the basis of ongoing research (Mannino, 2002; 
Weiss et al., 2003). 
 
2.5.3 Gender  
International trends suggest an increase in smoking behaviour amongst females and young 
adults even with intensive and ongoing anti-smoking campaigns worldwide (Mannino, 2002). 
In the past, the prevalence of smoking amongst males contributed to the higher rate of COPD 
in this group compared to females but recent trends indicate an increase in the occurrence of 
smoking in females, which has resulted in an increased development of COPD in this gender 
grouping (Hurd, 2000).  
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The differences in response to smoking and therefore the development of COPD could be as 
a result of females being more sensitive to the detrimental effects of cigarette smoke, possibly 
due to reduced airway size or increased  airway hyper-responsiveness and hormonal 
influences compared to males (Weiss et al., 2003). The female population are however twice 
as likely to be diagnosed with chronic bronchitis or asthma compared to males, reflecting a 
component of under-reporting of COPD as the primary diagnosis especially relating to 
females (www.lungusa.org/site/apps/s/content.asp, accessed 05 December 2006; Weiss et 
al., 2003). 
 
2.5.4 Airway responsiveness and allergies 
Airway hyper-responsiveness and atopy may predispose an individual to lung function decline 
and the development of COPD (Weiss et al., 2003). The presence of adolescence asthma 
and allergies can be indicative of developmental delays in full lung growth during childhood 
(Weiss et al., 2003). This can influence the development of COPD and lung function decline 
in a certain group of patients (Emtner, 1999; Weiss et al., 2003).  
 
In asthma, there is variability of airflow with airway hyper-responsiveness and inflammation as 
a result of an allergic response to trigger irritants, which leads to mucosal oedema, 
bronchospasm and plugging of the airways with mucus. Asthma as the diagnosis is 
differentiated from COPD in its response to bronchodilator therapy (Mannino, 2002). If a 
significant improvement in FEV1 occurs post inhaled bronchodilator of more than 80% 
predicted this usually confirms the diagnosis of asthma rather than COPD (Bateman et al., 
2004). This obstruction to airflow is either spontaneously reversible or through treatment, and 
this also distinguishes asthma from COPD, although a small percentage of COPD patients 
may have a reversibility component, as seen in asthmatics (Mannino 2002).  
http://scholar.sun.ac.za
 14
 
2.5.5 Occupational pollutants 
In the workplace, chronic exposure to substances such as grain, isocyanates, cadmium, coal, 
adhesives and welding gas may play a role in the development of COPD, although less than 
that of tobacco smoke (Boschetto et al., 2006). Using data from the Third National Health and 
Nutrition Examination Survey conducted in the United States from 1988 to1994, found the 
exposure to pollutants in the work place resulting in COPD was an estimated 19 % overall 
and 31 % amongst non-smokers (Hnidzo et al., 2002).  
 
This survey was designed to assess the health and nutritional status of the United States 
population and therefore did not necessarily reflect a wide spectrum of occupations. This 
study looked at occupations such as textiles and manufacturing, food manufacturing, car 
repair services, and occupations that involve exposure to chemicals, petroleum and others 
similar materials, but due to the limitations in the study design may have excluded other high 
risk occupations contributing to COPD. Mine workers, for example, are exposed to mining 
dust, especially in South Africa. This situation presents an occupational hazard as it can affect 
the lungs, predisposing workers to chronic lung disease (Weiss et al., 2003). 
 
2.5.6 Infections 
Susceptibility to early childhood respiratory tract infections such as bronchitis, pneumonia, 
colds and flu may result in a faster decline of lung function and predispose an individual to 
develop COPD (www.goldcopd.com/, accessed 21.12.2007; Mannino, 2002; Weiss et al., 
2003). Recurrent infections reduce maximal obtainable lung growth in childhood and if these 
young people are exposed to the risk factors associated with COPD, especially tobacco 
smoke in adolescence they are more likely to develop COPD (Celli et al., 2004). 
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TB is caused by the inhalation of the bacilli from an infected individual. This then causes an 
inflammatory lesion within the alveoli resulting in fibrotic areas and cavitatory lesions within 
the lungs. Secondary, TB develops when an individual’s immunity is compromised, and when 
poor nutrition and poor socioeconomic circumstances prevail (www. who Tuberculosis.htm, 
accessed 14.08.2006). It is the structural lung changes that develop post TB that emulate the 
characteristics of COPD. 
 
TB, as a bacterial infection, is particularly important in the South African context as it is 
endemic to certain areas of the country, such as the Western Cape, and is a known risk factor 
for COPD as it can result in fixed airflow obstruction, which is a characteristic of COPD ( 
Anderson and Phillips, 2006; Bateman et al., 2004). The incidence of TB per capita is nearly 
twice as high in sub-Saharan Africa compared to the South-East Asia region, which has the 
highest number of new TB cases globally (WHO Tuberculosis, 2006). However, TB as the 
primary diagnosis must be differentiated from COPD, especially in those areas that have a 
high prevalence of the disease, to support the correct management of these patients 
(www.goldcopd.com/, accessed 21.12.2007). 
 
2.5.7 Nutrition  
Some dietary supplements may have an impact on the development of COPD and research 
in this area is ongoing (Altose, 2003). The effect of nutrients on respiratory symptoms of 
bronchitis and wheezing were analysed by Schwartz and Weiss using data from the Second 
National Health and Nutrition Examination Survey in the United States (1990). They found a 
positive association between bronchitis and the sodium-to-potassium ratio but a negative 
association with the serum vitamin C and zinc-to-copper ratio. Wheezing was negatively 
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associated with serum vitamin C as well as niacin and the zinc copper ratio. In this study the 
interaction between smoking and nutrients was not significant.  
 
Shahar et al. (1994) studied the relationship between n-3 fatty acids dietary intake and COPD 
in a population-based study on atherosclerosis in 8960 current or former smokers. As n-3 
polyunsaturates are known to interfere with the body’s inflammatory response they may have 
an effect on chronic inflammatory conditions such as COPD. They concluded that a high 
intake of omega 3 fatty acids may protect smokers from COPD. Inconclusive evidence exists 
thus far regarding the effect of nutrition on either the prevention or predisposition of an 
individual to develop COPD. 
 
2.5.8 Smoking and environmental allergens 
Cigarette smoke is probably the most important health-related environmental factor and is 
recognised as a major risk factor of COPD as it causes an inflammatory reaction within the 
lungs, increasing blood leukocytes and decreasing the CD4+/CD8+T-lymphocyte ratio by 
increasing the CD8+ cells (Jeffery, 2002). This results in the breakdown of lung elastin, as 
well as increasing the rate of forced expiratory volume in one second (FEV1) decline (Weiss 
et al., 2003).  
 
Although a relatively small percentage of smokers (estimated at between 15–20%) eventually 
develop COPD, most of the patients diagnosed with COPD have a positive smoking history 
(Jeffery, 2002; Weiss et al., 2003). Smokers who continue to smoke have a worse prognosis 
and increased risk of death compared to non-smokers of the same age. Normal aging cause 
FEV1 to decline but it is accelerated in smokers; if a smoker stops smoking the lung damage 
is limited and slows the disease process (Anthonisen et al., 2002).  
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A study was carried out by the Lung Health Research group to determine if smoking 
cessation programmes and regular administration of an inhaled bronchodilator (ipratropium 
bromide) would change the forced expiratory volume in one second (FEV1) as well as the 
mortality and morbidity in smokers aged 35 to 60 (Anthonisen, et al., 1994; Anthonissen, et 
al., 2002). Results of this randomised clinical trail showed that the FEV1 in smokers who 
stopped at the beginning of the study declined at a rate of 30.2 ml/yr in males and 21ml/yr in 
females. In individuals who continued to smoke throughout the eleven years of the study, the 
FEV1 declined at an accelerated 66.1 ml·yr-1 in males and females at 54.2 ml·yr-1.  
 
The study was expanded to Lung Health Study 3, in which sought to determine whether 
differences persisted in the lung function of smokers eleven years after the original study. 
After the initial study, 38% of those who continued smoking and 10% of individuals who 
stopped smoking had their forced expiratory volume in one second (FEVו) value at less than 
60% of the predicted normal value. These results showed that the lung function of smokers 
declined at a significantly more rapid rate compared to those who had stopped smoking 
(Anthonisen et al., 2002).  
 
Although COPD is positively related to tobacco smoke, the non-affluent society of South 
Africa is more exposed to environmental air pollution than to actual tobacco smoke 
(Bradshaw and Steyn, 2001). Exposure to other causes of smoke inhalation such as in-house 
gases, burning coal and gases released from wood burning to cook and generate heat in the 
underprivileged communities also play a role in the development of COPD and contribute to 
the increased susceptibility of this group to develop COPD (www.goldcopd.com/, accessed 
21.12.2007).  
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2.6 Diagnosis of COPD 
The diagnosis of COPD is based on patient symptoms, spirometry, arterial blood gases, 
exercise testing and radiography. Patients, who complain of symptoms such as chronic 
cough, wheezing and increasing shortness of breath with activity, in the absence of any other 
lung pathology, should be considered and assessed for COPD. The symptoms associated 
with COPD such as a chronic and productive cough may present many years before 
substantial airflow limitation is evident.  
 
The presence and severity of airway obstruction in COPD is usually assed by means of 
spirometry and not peak flow. Spirometry is more sensitive to the reduction in forced 
expiratory flow than measuring the peak expiratory flow and is therefore used in the diagnosis 
of COPD and to establish the severity of the disease (Bateman et al., 2004; Weiss et al., 
2003).  
 
COPD and asthma are both obstructive lung diseases, but in asthma there are greater 
changes in airflow to trigger irritants whereas COPD is a slowly progressive disease with 
minimal symptoms early on in the disease (Weiss et al., 2003). Therefore the use of peak 
expiratory flow may be more valid when the diagnosis of asthma is suspected. The post 
bronchodilator FEVו together with the forced expiratory volume in one second/ forced vital 
capacity (FEVו/FVC) ratio is recommended by both SATS and GOLD to determine the 
diagnosis of COPD. A diagnosis of COPD is considered if the FEVו < 80%, predicted in 
combination with FEVו /FVC at a ratio < 70% (Bateman et al., 2004; Weiss et al., 2003).  
 
COPD usually presents insidiously and is categorized based on spirometry into four different 
stages. The SATS base their lung function values with regard to FEV1 on the European 
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Community for Steel and Coal (ECSC), with adaptations made for the South African 
population. Multiplication of spirometry values by 0.9 is advised for the ethnic groups of 
African and African American decent in the South African population (Bateman et al., 2004). 
At stage 0 (normal but at risk) and 1 (mild), the FEVו varies between ≥ 80% predicted and 60–
79% respectively. These patients may have minimal respiratory symptoms and experience 
less impact of symptoms on activities of daily living (Bateman et al., 2004). However at stage 
2 (moderate) and stage 3 (severe) the FEVı is 40–59% and < 40%, respectively. The patients 
exercise tolerance becomes severely affected and they may be prone to acute exacerbation 
(Bateman et al., 2004; MacNee, 2003). In the 2006 revision of the GOLD guidelines the 
recommended use of stage 0 was removed due to insufficient evidence for use in identifying 
individuals at risk to develop COPD and stage 4, very severe category included with FEV1 
<30% or FEV1 <50% with chronic respiratory failure(www.goldcopd.com/, accessed 
21.12.2007).  
 
2.7 Defining acute exacerbation 
In addition to everyday symptoms associated with the disease as experienced by COPD 
patients, they can suffer episodes of acute exacerbation. Acute exacerbations are more 
frequent in the moderate to severe stages of the disease. Currently, there is no universal 
agreement on the precise definition of acute exacerbation. Most literature refers to acute 
exacerbation as a clinical event that is dependent on the patient’s symptoms to aid diagnosis 
(MacNee, 2003). It usually refers to deterioration in the patient’s clinical status, with 
worsening of respiratory symptoms beyond the normal day-to-day variation experienced by 
the patient, requiring medical intervention (MacNee, 2003). The symptoms of acute 
exacerbation could include any of the following: an increase in coughing, wheezing and 
sputum production, and shortness of breath (Hunter and King, 2001).  
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Possible causes of exacerbations could include viral infections, bacterial infections, air 
pollution and cold weather; may be considered non-modifiable risk factors (Burge and 
Wedzicha, 2003). Other features that are considered modifiable by an individual and increase 
receptiveness to acute exacerbation include the lack of influenza immunisation, improper use 
of medication and continued smoking behaviour (Weiss et al., 2003).  
 
The majority of acute exacerbations remain unreported. Many patients do not require 
hospitalisation and are treated at emergency departments and primary care centers, and then 
discharged home within twenty-four hours (MacNee, 2003). In its severe form however, acute 
exacerbation requires medical intervention, often resulting in hospitalisation. Although only a 
small percentage of patients may ultimately present with acute exacerbation severe enough 
that requires subsequent hospitalisation, this is nonetheless associated with high financial 
costs and reduced quality of life (QOL) due to possible readmission. The risk of 
hospitalisation increases with increasing age, declining lung function and moderate to severe 
COPD (Fan et al., 2002). 
 
2.8 Current management of COPD 
The emphasis in the management of COPD prior to the GOLD guidelines was predominantly 
aimed at improving lung function and limiting lung function decline through pharmacological 
interventions (Wouters et al., 2000). This has changed in line with the GOLD developments 
and ongoing research; guidelines are now aimed at managing symptoms and improving the 
quality of life of the COPD patient (www.goldcopd.com.com/ accessed 21.12.2007)  
 
The GOLD guidelines were developed and implemented to consolidate the battle against this 
disease, in the light of the escalating burden of COPD and acute exacerbation. The guidelines 
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were formulated in an attempt to increase awareness of COPD as well as establishing 
guidelines for health care professionals dealing with this disease that is evidence based. The 
National Heart, Lung and Blood Institute (NHLBI) (USA) and the WHO formally launched the 
Global Initiative for Obstructive Lung Disease (GOLD) in 2001. The GOLD document provides 
a set of guidelines to assist with the implementation of the proposed draft document 
worldwide. The objectives of the programme were to:  
 Recommend effective COPD management and preventative strategies for use in all 
countries. 
 Increase awareness of the medical community, public health officials and the public 
that COPD is a public health problem. 
 Decrease morbidity and mortality from COPD through implementation and evaluation 
of effective programmes for the diagnosis and management. 
 Promote research into the reasons for increasing prevalence of COPD, including the 
relationship with the environment. 
 Implement effective programmes to prevent COPD ( Pauwels, 2001) 
 
The South African Thoracic Society (SATS) established a similar programme and developed 
guidelines specific to the South African population. Important components of these guidelines 
include both the prevention of exacerbations as well as improving the quality of life of patients 
with COPD (Bateman et al., 2004). These guidelines also include: 
 recognition of the disease 
 smoking cessation to arrest disease progression 
 improving breathlessness through treatment of airflow obstruction, based upon grading 
of severity 
 improvement of quality of life 
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 increasing awareness of the effects of COPD on the South African population 
 the importance into the exposure to domestic and occupational atmospheric pollution, 
previous lung infections and TB. 
 prevention and treatment of complications (Bateman et al., 2004). 
 
The current management of COPD focuses on assessing and monitoring the disease, 
reducing risk factors, managing stable COPD and managing exacerbations through 
pharmacological therapy, long-term oxygen therapy (LTOT) and pulmonary rehabilitation 
(www.goldcopd.com/, accessed 21.12.2007; Hunter and King, 2001; O’Donnell, 2002; 
Pauwels, 2003; Sullivan et al., 2003).  
 
The management of acute exacerbation includes a combination of the following: use of 
bronchodilators, corticosteroids, antibiotics, oxygen therapy, mucolytic agents and treatment 
techniques, as well as non-invasive positive pressure ventilation (Snow et al., 2001). 
 
The benefit of including pulmonary rehabilitation programme in the management of COPD 
and acute exacerbation will be dealt with in section 2.8.1 as pharmacology aims to control the 
symptoms of the disease to improve the quality of life of patients whilst pulmonary 
rehabilitation has a greater impact on the latter (Snow et al., 2001). 
 
 
 
2.8.1 Pulmonary rehabilitation 
As COPD is a debilitating disease that affects the patients’ mental and physical ability as well 
as health-related quality of life (HRQOL), increasing emphasis is therefore placed on 
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treatment that will improve the individuals’ quality of life, as pharmacological therapy only 
relieves the symptoms but cannot change the lung function decline (Gϋell et al., 2000).  
 
Pulmonary rehabilitation attempts to improve the individuals’ quality of life through a 
programme designed specifically to target problem areas, although it cannot alter the existing 
lung damage. Some of the overall benefits of rehabilitation include an increased exercise 
capacity, increased daily living activities, decreased episodes of acute exacerbation, a 
decrease in dyspnoea, a decrease in anxiety and depression, and decreased costs 
associated with hospitalisation (American Thoracic Society (ATS), 1999; Fahy, 2003). These 
benefits may contribute to evidence in support of studies indicating that patients participating 
in an exercise programme experienced fewer days in hospital when readmitted and a 
reduction in exacerbation, and therefore a decrease in cost associated with hospitalisation 
(Güell et al., 2000; Puhan et al., 2005). The initial cost of starting a pulmonary programme 
might be high but it may be offset by the benefits achieved in the rehabilitation programme.  
 
The components of a comprehensive pulmonary rehabilitation programme comprise any 
combination of the following: exercise programme, education, behavioural intervention, and 
nutrition and outcome assessment. The programme is usually conducted by a team of 
professionals, including a physiotherapist, psychologist, physician, occupational therapist, 
dietician, social worker and biokinetician (ATS, 1999).  
 
Exercise training forms an integral part of pulmonary rehabilitation and the benefits thereof 
have been well researched. These include improvement in strength and movement, 
endurance and a general feeling of wellbeing due to the underlying effects of increased blood 
flow. The benefits of exercise training may be most beneficial in the reduction of dyspnoea, 
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which is the most common complaint of COPD patients. In Stage1 pulmonary rehabilitation 
may not be considered as vital due to the absence or minimal presentation of symptoms. In 
the moderate and severe stages however, due to declining lung function, with increasing 
symptoms and consequent decrease in quality of life (QOL), pulmonary rehabilitation 
becomes an essential component in the patients’ management. Pulmonary rehabilitation is 
particularly important post acute exacerbation when the patient may experience either a 
temporary or permanent decrease in the quality of life (Fahy, 2004).  
 
Güell et al. (2000) conducted a randomised controlled trail of 60 moderate to severe COPD 
patients aged ≤ 75, with mean lung function values of FEV1 35 ± 14% over  a one year period 
and which included a two-year follow-up period as part of an outpatient rehabilitation 
programme in Barcelona, Spain. Patients were randomly assigned into a control or 
rehabilitation group, with the control group receiving standard medical treatment that included 
conventional pharmacological therapy, while adding rehabilitation in the pulmonary 
rehabilitation group and chest physiotherapy if needed. The pulmonary rehabilitation group 
received six months of intensive rehabilitation and a six-month maintenance programme. The 
rehabilitation patients reported an improvement in exercise ability on the six-minute walk test, 
and decrease in fatigue, dyspnoea and emotional function, as measured on the chronic 
respiratory questionnaire (CRQ). 
  
In an eight-week outpatient rehabilitation programme carried out by Jenkins et al. (2001), with 
57 patients, 49 of whom had COPD with the average FEV1 of the total number was 41.4% 
and the FEV1/FVC ratio 49.3% was studied. Exercise capacity improved and there was a 
significant improvement in the QOL as measured on the Chronic Respiratory Disease 
Questionnaire (CRDQ) and the Short Form–36 item questionnaire (SF-36).  
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Reis et al. (1995) also conducted a randomised clinical trail to compare the effects of a 
comprehensive rehabilitation programme with those of education alone on the physiological 
and psychosocial outcomes in patients with mild to severe COPD. A group of 119 outpatients 
were randomly assigned to either an eight-week rehabilitation programme or an eight-week 
education programme. The programme included twelve four-hour sessions for the pulmonary 
rehabilitation group including education, instruction on physical and respiratory care, 
psychosocial support and supervised exercise training; reinforcements sessions were held 
over a one-year period. The education group attended four two-hour sessions that included 
videotapes, lectures and discussions. In comparison with the education group the 
rehabilitation group showed significant changes in exercise performance and symptoms. The 
results supported those of other studies by demonstrating improvements in exercise 
performance and symptoms for patients with moderate to severe COPD. The benefits of this 
programme were maintained for about one year but decreased over a two-year period.  
 
2.9 Outcomes of COPD 
At present, the acknowledged outcomes that have been explored in COPD are health care 
utilisation, HRQOL, physiological factors and mortality. All of these are aimed at improving the 
implementation of available preventative strategies (Camargo, 2002; Groenewegen et al., 
2003; Sullivan et al., 2003).  
 
2.9.1 Health care utilisation  
COPD has been recognised as a growing health problem with an increasing impact on the 
medical field, society and the economy (Altose, 2003). This is especially evident in the direct 
medical management of the disease and indirect medical expenses in terms of lost income, 
caregivers, social isolation and physical disability attributed to the disease. The disease 
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process follows a chronic progressive course, resulting in increased utilisation of health 
services and concomitant increased health expenditure with time, as the patient grows older 
and the disease advances (www.lungusa.org/site/pp.asp, accessed 17 March 2005; Mannino 
et al., 2002).  
 
COPD patients can experience up to three exacerbations per year. Up to half of these may be 
unreported as they may not be severe and not require medical intervention. Patients with a 
strong smoking history, for example of more than a 40 packs per year, may experience an 
increase in the severity and number of episodes of acute exacerbation (Francioisi et al., 
2006). Patients with mild COPD may have fewer exacerbations compared to the moderate to 
severe COPD patients, who can experience more than three exacerbations per annum 
(MacNee, 2003). Initially there may be minimal symptoms not severe enough to limit activity 
as the respiratory system adapts to the pathophysiological changes occurring within the 
lungs. As the disease advances, increasing symptoms due to declining lung function will limit 
the simplest of tasks in the severe stages of the disease (O’Donnell, 2006).  
 
In 1998, outpatient hospital or doctors’ COPD visits accounted for an estimated 14.2 million 
visits in the United States, and in the same year there were 662,000 hospitalisations of 
patients with COPD (Mannino, 2002). The hospitalisation of patients where COPD is the main 
or contributing cause of admission continues to place a burden on the elderly; hospitalisations 
were highest in the age group 65–75 years at 19.9 %, over 75 years at 18.2 %, and slightly 
lower at 14.8 % for the 55–65 years age group (Mannino, 2002). In 2002, hospital COPD 
discharges in the United States were an estimated 675,878; the highest were amongst the 65 
years and older group, at more than 65 % (www.lungusa.org/site/pp.asp, accessed 17 March 
2005). The economic cost of lung diseases in the US is expected to increase to $144 billion, $ 
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87 billion in direct health expenditure and $ 57 in indirect cost of mortality and morbidity 
(NHLBI, 2006). 
 
A significant portion of the economic expenditure associated with COPD is due to 
hospitalisation as a result of frequent readmissions of patients with acute exacerbation (Fan 
et al., 2002; www.goldcopd.com/, accessed 21.12.2007). In 2001 acute exacerbations 
accounted for about 500 000 hospitalisations in the United States alone and $18 billion in 
direct health care costs (Snow et al., 2001). In the UK Health Authority, which serves a 
population of 250 000, hospitalisations specifically due to acute exacerbation have been 
estimated to be about 680 per annum (MacNee, 2003). No specific information in South Africa 
exists on the hospitalisation of COPD patients diagnosed with acute exacerbation, following a 
search of the electronic databases of Medical Research Council of South Africa and Statistics 
South Africa.  
 
A range of factors may influence hospitalisation as COPD patients are generally older and 
have other associated medical conditions that can contribute to hospitalisation 
(www.goldcopd.com/, accessed 21.12.2007). The presence of co-morbidities such as 
cardiovascular disease or cancer can influence the course of COPD and result in more 
hospitalisations, but some debate still surrounds this aspect as not all studies performed have 
demonstrated similar results (Bateman et al., 2004; Garcia-Aymerich et al., 2001; Seemungal 
et al., 1998; Sullivan et al., 2003). However, hospitalisation may be based on a variety of 
factors: a low body mass index (BMI), poor performance on the 6-minute walk test, gas 
exchange impairment, the use of long term oxygen therapy (LTOT) as well as haemodynamic 
dysfunction (Kessler et al., 1999). The COPD Guideline Working Group of the SATS (2004), 
in their guidelines for hospitalisation of acute exacerbation, included factors such as infection, 
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pneumonia, deterioration in mobility and new arrhythmia as this can also contribute to 
hospitalisation, is in agreement with what is proposed by Burge et al. (2003) and MacNee 
(2003). 
 
Medicare, an American health insurance programme, provides cover for persons over the age 
of 65 years, persons eligible for social security disability benefits and persons who have renal 
failure. Their statistics of 1991 showed that the length of stay averaged 7 days in hospital for 
acute exacerbation and the expenditure per capita was 2.4 more than normal COPD cases – 
most of the costs were being incurred in hospital (Fan et al., 2002). A study by Connors et al. 
(1996) carried out to investigate the outcomes of patients hospitalised with acute 
exacerbation documented the median length of stay at 9 days after admission for acute 
exacerbation. At present, there are no definitive data to determine the ultimate duration of 
hospitalisation for patients with acute exacerbation as the reasons for admission may be 
complex, which therefore require a longer hospitalisation period. Patients may have 
associated medical conditions that may influence the length of stay and not simply the 
primary diagnosis of acute exacerbation of COPD (Pistelli et al., 2003). 
 
 Patients requiring ICU admission and ventilation may ultimately have a longer hospitalisation 
period. Groenewegen et al. (2003) found that COPD patients hospitalised with acute 
exacerbation spent an average of 10 days in hospital, compared to ICU patients who stayed 
for 16.5 days.  
 
Sin et al. (2000) carried out a study to determine if elderly patients over 65 years of age with 
shorter lengths of stay had higher readmission rates and mortality compared to those patients 
who stayed longer. They found that although patients younger than 74.8 years (±6.9 SD) of 
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age had shorter hospital stays, they were more frequently readmitted. This population-based 
study conducted over a 5-year period, from 01 April 1992–31 March 1997, in Ontario, Canada 
grouped COPD and asthma in one category. This limits the validity on the COPD population 
as asthma is managed differently due to the variability of its symptoms. In this study, the 
patients who stayed less than 4 days were 39 % more at risk of readmission and 45 % more 
likely to die within two weeks post discharge although they were younger than those who 
stayed longer. 
 
The SATS have published proposed discharge criteria in their “Guideline for the Management 
of COPD” revision (2004), which are similar to trends in the United Kingdom. These 
guidelines include the following: COPD education, assessment of further need for oxygen, 
written home-action plan, rehabilitation, plan for smoking cessation, assessment of home 
conditions and psychosocial support. International recommended criteria for hospital 
discharge also support the following criteria: symptoms return to baseline, haemodynamic 
stability, oxygenation return to baseline, inhaled β-antagonist therapy required less frequently, 
ambulation resumed, ability to eat and sleep without frequent waking caused by dyspnoea, off 
parenteral therapy for 12–24 hours, patient and home carer understands correct use of 
medication, and follow-up home care arrangements (Celli et al., 2004). All or any of these 
factors can contribute to a shorter or eventual longer length of stay in hospital. 
 
 
2.9.2 Health related quality of life  
Health related quality of life (HRQOL) refers to changes in daily life and well-being affected by 
the disease and are usually measured by means of disease specific questionnaires or generic 
measurements, such as the St George’s Respiratory Questionnaire (SGRQ), Chronic 
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Respiratory Disease Questionnaire (CRDQ), Chronic Respiratory Questionnaire (CRQ), Short 
Form 36-item questionnaire (SF-36), and others (Jones 1997; Mahler 2002; Siafakas et al., 
1997).  
 
The use of HRQOL tools may not necessarily influence changes in actual medical 
management but may indicate the effect of the disease on an individual’s standard of living 
(Katula et al., 2004). Patients may experience their deteriorating health status vastly different 
compared to the severity of COPD expressed in terms of physiological measurements of the 
FEV1 (Garrido et al., 2006). In their study on the negative impact of COPD on the HRQOL of 
patients, Garrido et al. (2006) found that even in the mild stages of the disease, patients may 
experience deterioration in HRQOL and females had lower HRQOL levels than males. Their 
study was carried out on stable COPD patients in a primary care setting using physician 
visits, health care centres and medical records. They reported the best predictors of poor 
HRQOL to be gender, FEV1, use of oxygen therapy, emergency room visits and hospital 
admissions. 
 
Fan et al. (2002) carried out a study to determine whether a self-administered questionnaire, 
the Seattle Obstructive Lung Disease Questionnaire (SOLDQ), a condition-specific QOL 
measure, could accurately predict hospitalisation and mortality. Patients with poor quality of 
life were found to have an increased risk for these outcomes. This study was however limited 
to the United Stated male veteran population and the SOLDQ results were only compared to 
those obtained from the SF-36 and hence results can only be interpreted in that context.   
 
A survey conducted by means of telephonic interviews with patients and physicians in the 
United States from August to November 2000 revealed that 51 % of COPD patients found 
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their condition limited their ability to work effectively (American Lung Association, 2001). 
Limitations in other areas were also experienced: normal physical activity 70 %, household 
chores 56 % and social activities 53 %. COPD may be also a limiting factor for individuals to 
perform at their peak even in the mild stages of the disease (American Lung Association, 
2001).  
 
In a study of the effect of exacerbation on QOL in patients with COPD, Seemungal et al. 
(1998) established that the frequent exacerbation group had poorer scores on the SGRQ 
compared to the infrequent exacerbation group. In this study they measured the daily peak 
expiratory flow rate (PEFR), daily respiratory symptoms and QOL on the SGRQ using the 
patients’ daily diary cards and clinic visits to record the information. Although patients only 
reported 50% of exacerbations, there were no differences in peak flow or symptoms during 
reported exacerbation and unreported episodes. In this study, the use of FEV1 and especially 
the PEFR are limiting factors, as they are not ideal measurements during an exacerbation. 
This is because both the daily PEFR, which poorly reflects the severity of COPD, and lung 
function measurements expressed by means of the FEV1 are very difficult to perform during 
exacerbations (Snow et al., 2001). 
 
COPD patients experience dyspnoea more severely and faster when exercising compared to 
healthy subjects. This is the most common symptom limiting activity in COPD patients 
(O’Donnell, 2006). This is due to lung hyperinflation caused by expiratory flow limitation and 
destructive changes within the lungs, with resultant dyspnoea. Patients usually attempt to limit 
their activities so as not to induce shortness of breath (SOB) and become increasingly 
anxious of becoming SOB, with resultant muscle deconditioning (Hill et al., 2004). Repeated 
readmissions have been shown to result in muscle deconditioning and contribute to reduced 
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quality of life, due to immobility imposed in an attempt to decrease dyspnoea (Puhan et al., 
2005; Siafakas et al., 1997).  
 
2.9.3   Physiological factors  
Body mass index 
Damage resulting from COPD extends further than the lungs. It has a significant systemic 
component in terms of muscle dysfunction, muscle wasting, osteoporosis and weight loss 
(Andreassen et al., 2003; Bolton et al., 2004). Increasingly, body weight is recognised as an 
important factor in COPD; unexplained weight loss in this group is of great concern as it 
indicates severe disease and places patients at risk of early mortality (MacNee, 2003). Body 
weight is calculated as the sum of fat mass and body cell mass (BCM), and is measured by 
establishing the fat-free mass (FFM) as this is easier to determine than the body cell mass. 
The BCM is an indicator of the amount of actively metabolising and contractile tissue, 
including muscle mass. It is rather difficult to establish the lean muscle mass and therefore 
the FFM index is used (Wouters, 2000).  
 
In general terms, weight loss and loss of fat mass is described as the result of an imbalance 
between energy expenditure and nutritional intake (Andreassen et al., 2003). Patients with 
COPD have a higher resting energy expenditure compared to normal individuals; their energy 
expenditure from the disease process exceeds the nutritional intake and nutritional 
supplements may not necessarily complement the shortcomings. However, weight loss and 
specifically muscle wasting in COPD is mediated by a number of factors. These factors 
include malnutrition as well as hypoxia, pulmonary inflammation, protein synthesis and protein 
breakdown, as well as an imbalance in the hormones involved in this process (Debigaré et al., 
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2001; MacNee, 2005). Initially, body weight may be maintained in the early stages of the 
disease but muscle wasting may be present, and rapid and unexplained weight loss becomes 
more evident as the disease progresses (Garcia-Aymerich et al., 2003).  
 
BMI is calculated using the weight/metre² (kg/m²). Normal BMI is considered to be between 
21 kg/m² and 25 kg/m², and patients can be grouped in underweight < 21 kg/m² and 
overweight > 30 kg/m² categories (Bateman et al., 2004; Celli et al., 2004). COPD patients 
who present with a BMI of less than 21 kg/m², compared to individuals with a BMI > 26kg/m², 
are reported to have a 50% mortality rate (Bateman et al., 2004; Landbo et al., 1999). Current 
evidence increasingly suggests that the impact of a low BMI may be one of the important 
factors to consider when deciding on hospitalisation of the COPD patient, and it can influence 
survival (Landbo et al., 1999). 
 
In a study conducted by Bolton et al. (2004) on the associated loss of fat-free mass and bone 
mineral density (BMD) in COPD they demonstrated an association between the loss of BMI 
and BMD, and greater losses with severe disease. In their study 81 clinical stable COPD 
subjects and 38 healthy subjects were subjected to dual-energy X-ray absorptiometry to 
determine body composition and BMD. Urinary protein breakdown markers, inflammatory 
mediators and their soluble receptors were also determined. Their results indicated the loss of 
fat free mass and BMD was related and that greater losses occurred in subjects with severe 
lung disease.  
 
All of the above factors contribute to muscle weakness and eventually atrophy, increasing the 
risk of respiratory muscle dysfunction and mortality in the underweight patient (Bateman et al., 
2004; Wouters, 2000). Underweight patients may also have weaker respiratory muscles 
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compared to patients of normal weight and present with increased reports of dyspnoea (Hill et 
al., 2004; O’Donnell 2002; Wouters, 2000). Patients adapt their lifestyles accordingly to avoid 
becoming short of breath and this, combined with poor nutritional status and possible steroid 
myopathy could exacerbate the problems associated with muscle weakness (Wouters, 2000). 
Long-term corticosteroid use in COPD patients can cause myopathy and worsen the problem 
of muscle weakness (Wouters, 2000). The underweight patients in treatment are usually 
given nutrition supplements. 
 
Blood gas abnormalities 
The main function of the lungs is ventilation and perfusion, which is helped by muscle 
contraction and the measure of elasticity of the lungs. During inspiration the airflow into the 
alveoli is produced by a pressure difference caused by contraction of the intercostal muscles 
and the diaphragm. This allows for expansion of the lungs and ribcage, increasing the 
intrathoracic pressure (Soicher et al., 1998). Inspiration is an active process whereas 
expiration is a passive process, occurring when the stretched elastic tissue recoils and forces 
all the inspired air out of the lungs. Due to the destruction of the alveoli in emphysema the 
surface area in contact with the capillaries is reduced, causing inadequate gas exchange. In 
chronic bronchitis mucus hyper-secretion obstructs the airways, resulting in poor ventilation. 
As a result of the changes associated with emphysema and chronic bronchitis within the 
lungs and supporting structures the normal functioning ability of the lungs is affected, resulting 
in hypoxaemia with or without hypercapnia (Jones et al., 2003).  
 
Blood gas abnormalities normally worsen during an acute exacerbation but the patient’s pre-
hospitalisation status needs to be considered as many COPD patients suffer from chronic 
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hypercapnia. A low PaO2 of less than 6.7 kPa (50 mmHg), high PaCO2 and a pH lower than 
7.35 could indicate acute respiratory failure and require hospitalisation (Kessler et al., 1999). 
 
The prescription of LTOT is indicated in patients who present with oxygen saturation below 
90% at rest or who are hyoxaemic, with or without hypercapnia, and who do not smoke. Due 
to the combustible nature of oxygen it is not advisable to prescribe LTOT in those patients 
who continue to smoke. Use of LTOT has resulted in a decrease in respiratory failure and 
associated complications because of reduced hypoxemia on the vital organs, and hence there 
is an improved survival rate (Bateman et al., 2004; Hunter and King, 2001). Patients with 
home oxygen may have a reduced need for hospitalisation but are required to use oxygen for 
at least 16 hours a day (Bateman et al., 2004). The under-prescription of LTOT has however 
been associated with an increase risk for hospitalisation (Garcia-Aymerich et al., 2001). 
 
Haemodynamic status 
Amongst the many complications associated with COPD, secondary pulmonary hypertension 
is considered one of the important problems of this disease. Pulmonary hypertension and 
right ventricular failure may occur due to an increase in pulmonary artery pressure due to 
continuous pulmonary vasoconstriction. Although the effects of hypoxia on the pulmonary 
arterioles is considered the main reason for this vasoconstriction, chronic inflammation, 
structural changes and eventual destruction of the pulmonary vascular bed all contribute to 
secondary pulmonary hypertension (Hopkins et al., 2002; Morrell et al., 2005). It is associated 
with high mortality and may be more evident in patients with severe lung disease (Morrell, 
2005). 
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2.9.4 Mortality  
In South Africa, COPD is classified under the umbrella term of non-communicable diseases. 
In the period 1997–2004 there was a slight increase in the number of deaths for males 
between the ages 55–59 and females 45–54 years. Communicable infectious diseases such 
as TB demonstrated a significantly greater increase in prevalence (Anderson and Phillips, 
2006). In a study conducted in Cape Town and sub-districts on the causes of death and 
premature mortality, COPD was in 11th position (homicide, ischaemic heart disease and 
HIV/AIDS were amongst the top three) (2001). The same study showed the following results: 
death rates and premature mortality (expressed as years of life lost) due to COPD for males 
were higher than for females: the former (males) were ranked eight and tenth respectively, 
and the latter (females) tenth and nineteenth, respectively.  
 
Although COPD did not account for substantial and dramatic increases in mortality, it is still 
amongst the top 10 causes of deaths in both the Tygerberg East and West districts. In Cape 
Town and the 11 sub-districts where data were collected on the 10 most common causes of 
death, COPD as a cause of death was present in eight of the areas (Groenewald et al., 2001). 
   
COPD accounted for the highest percentage of the deaths, at 42%, followed by stroke 34.5% 
then asthma 34.3% in the non-communicable disease category in South Africa (Bradshaw 
and Steyn, 2001). These statistics were taken from the 1996 death registry of South Africa. 
However, statistics on mortality in South Africa from this timeframe have to be interpreted with 
care as a large percentage of death were ‘misclassified’ (15%) and an estimated 20% of 
deaths were not registered in the death registry of 1996. The figures are nevertheless 
indicative of the effect that COPD has on the South African population.  
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In the United States COPD accounted for 4% of all deaths in 1995, and in 2002 it was the 
fourth leading cause of death preceded only by heart attacks, cancers and strokes (NHLBI, 
2006). The death rate among men remained stable in the United States but at the same time 
in the period from 1993–2003 increased in the female population. This could be due to the 
increased incidence of cigarette smoking in this group (Hurd, 2000; NHLBI, 2006). The death 
rate of females in the United States compared to their counterparts in countries like England, 
France, Finland, Australia, Japan, Poland and Germany also increased substantially between 
1980 and 2003 (NHLBI, 2006). 
 
The follow up of patients admitted with acute exacerbation showed a 49% increase in 
mortality rate at two years post-hospitalisation and a high readmission rate in the study by 
Connors et al. (1996). In this study of 1016 patients admitted with acute exacerbation it was 
found that the severity of illness, BMI, age, prior functional status, PaO2, congestive cardiac 
failure, serum albumin and the presence of cor pulmonale were independently related to 
survival time (1996). 
 
In COPD a high PaCO2 and chronic hypercapnia were identified as factors contributing to an 
increased risk for mortality by Groenewegen et al. (2003). In their study, all COPD patients 
hospitalised with acute exacerbation were followed up for a period of one year to assess the 
mortality rates and potential determinants of mortality in hospital and over the one-year 
period. Patients requiring Intensive Care Unit (ICU) admission for acute exacerbation have 
been associated with higher mortality rates as they are critically ill and usually require 
ventilation (2003). A further study conducted by Gudmundsson et al. (2006) on mortality of 
COPD patients discharged from hospital, however, found diabetes to be one of the most 
important risk factors for mortality post-admission of COPD patients.  
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Developing countries are gradually becoming more exposed to western influences and could 
suffer a substantial burden of increase in the prevalence of chronic diseases such as COPD, 
cardiovascular disease, and other diseases now actively combated in developed countries 
through proactive campaigns on health education, anti-tobacco legislation and lifestyle 
changes, as well as improved access to health services (Bradshaw and Steyn, 2001). 
Although life expectancy and mortality rates do not indicate the exact state of health of a 
population, the figures can assist in the decision-making process as to where resources 
should be distributed, as it reflects the impact of diseases on the population (Michaud, 2001).  
 
The need to ascertain the impact of COPD on a developing country such as South Africa is of 
paramount importance, particularly as the disease causes significant functional disability that 
translates into vast socio-economic consequences (Michaud, 2001). In this context, would the 
profile of the South African COPD patient admitted with acute exacerbation be similar to 
patients in the developed countries? 
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Chapter 3 
 
Methodology 
 
3.1 Introduction 
In this chapter the methodology used to answer the research question will be described and 
discussed. The setting in which the research was carried out will be described. The patient 
identification, sampling procedure, development of the instrument, data compilation and data 
capture are also explained in this chapter. 
 
3.1.1 Research question 
What is the profile and selected outcomes of Chronic Obstructive Pulmonary Disease (COPD) 
patients admitted with acute exacerbation to hospitals in the northern suburbs of the Western 
Cape? 
 
3.1.2 Objectives of the research  
1) To describe the demographics of the COPD patient hospitalised with an acute 
exacerbation to Tygerberg Hospital, Karl Bremer Hospital and Panorama Medi-Clinic 
with reference to: 
 age 
 height 
 weight  
 gender 
 smoking history  
 socio economic status 
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 co morbidities 
 
2) To describe the present and past clinical presentations of acute exacerbation requiring 
hospitalisation in a 12-month period in relation to: 
 respiratory rate 
 pulse 
 blood pressure 
 temperature 
 oxygen saturation 
 arterial blood gases 
 lung function values 
 reason for admission 
 
3) To describe selected outcomes of COPD patients admitted with acute exacerbation in 
relation to: 
 length of stay in hospital. 
 number of readmissions for acute exacerbation in the previous year.  
 
3.2 Study design 
The study design was a multicentre retrospective observational study.  
 
3.3 Setting 
The hospitals that participated in the study included two public hospitals-a tertiary and a 
secondary health care facility and one private health care facility.  
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3.4 Population 
All COPD patients that were hospitalised in the selected secondary, tertiary and private 
institutions in the northern suburbs of the Western Cape. 
 
3.5 Sample  
A sample of convenience was used. The following hospitals were selected as they are within 
20 km of each other, which facilitated the logistics of data collection. 
 Tygerberg Hospital 
 Karl Bremer Hospital 
 Panorama Medi-Clinic 
 Louis Leipoldt Medi-Clinic 
 
3.5.1  Inclusion criteria 
Subjects were included if they had the diagnosis of COPD: 
  They were hospitalised with an acute exacerbation. 
  They were admitted during the period 01June 2004–01June 2005.  
 
3.5.2 Exclusion criteria 
Subjects were excluded if: 
 They were discharged within 24 hours from the ward or emergency departments of all 
the involved hospitals. 
 They died within 24 hours of admission. 
http://scholar.sun.ac.za
 42
 The medical folders were unattainable by the researcher after two submissions to the 
medical records department. 
 The institution did not give permission for the study to be conducted at their facility.  
 
3.6 Instrumentation 
The researcher developed the following data capturing sheets based on a review of current 
literature and after consultation with various physiotherapists and physicians, to obtain the 
relevant information required for the study.  
 
3.6.1 Patient data capture sheet (Addendum A) 
The data capture form was developed to record patient characteristics, the reason for hospital 
admission and the present medical condition of the patient. All information was gathered 
retrospectively using the medical folder of the patient.  
 
Patient characteristics 
Based on literature, the following variables to establish a patient profile were included: age, 
weight, height, gender and socio-economic status (Garcia-Aymerich et al., 2001; 
Gudmundsson et al., 2006; Weiss et al., 2003). Refer to section 2.5.1 -2.5.8. 
 
Reason for admission 
The complaints of an increase in dyspnoea, cough, sputum and sputum purulence are the 
most common symptoms when experiencing an acute exacerbation (Weiss et al., 2003) and 
were hence included in this section. In the development of this section, indication for 
hospitalisation as contained in the SATS 2004 document and current trends were taken into 
account (MacNee, 2003). Refer to Section 2.9.1. 
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Present medical condition 
Physiological values in respect of oxygen saturation, temperature, pulse, respiratory rate, 
arterial blood gases and lung function values were used to document the status of the patient 
on initial presentation and this information was therefore included on the data forms (Franciosi 
et al., 2006; Kessler et al., 1999). FEV can be used as an indicator of disease severity. It 
declines at a more rapid rate as the disease advances, especially in smokers, and lung 
function values were thus included in this section (Weiss et al., 2003). Refer to Section 2.9.3. 
 
3.6.2 Readmission data capture sheet (Addendum B) 
This data capture form was developed to record the patient’s previous hospitalisations due to 
acute exacerbation, co-morbidities and vital signs. 
 
Readmission 
Patients may be at increased risk of readmission once hospitalised with an acute 
exacerbation (Snow et al., 2001). Repeated hospitalisation of COPD patients with acute 
exacerbation is linked to reduced Quality Of Life, as well as being an indicator of disease 
severity (Burge and Wedzicha, 2003; MacNee, 2002). Refer to section 2.9.1. 
 
Past medical history  
Patients over 50–60 years of age frequently have associated diseases such as cancer and 
cardiovascular conditions that may have an effect on the course of COPD (Burge and 
Wedzicha, 2003; Sullivan et al., 2003). Refer to section 2.9.1. 
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Length of stay 
At present there are no definitive data to determine the ultimate duration of hospitalisation for 
patients suffering acute exacerbation. A shorter hospitalisation period may indicate worse 
outcomes, but this has not been definitively established (Burge and Wedzicha, 2003). Refer 
to section 2.9.1.  
 
3.7 Medication data capture sheet (Addendum C) 
This data capture sheet was developed to document the medication prescribed to the patients 
during acute exacerbation. 
 
3.8  Patient confidentiality data capture sheet (Addendum D) 
This data capture sheet was developed to ensure patient confidentiality and anonymity, by 
delegating a numerical code to the patient’s name. The patient’s name and folder number 
was recorded on this form and a specific number was designated to the patient’s name. The 
patient’s details were kept in a safe environment to enable the researcher to extract data from 
the patient’s medical folder when required, during the course of the research, where after it 
would destroyed. 
 
3.9 Patient identification 
Patients were identified by means of two procedures in the planning stage: a hospital and a 
medical folder procedure were put in place. The following systems were then established at 
the various hospitals to identify patients included in the sample: 
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Hospital procedures 
Panorama Medi-Clinic 
 Here all the wards have an admission and discharge book. These books were 
accessed to identify patients admitted with the symptoms of acute exacerbation within 
the period 01 June 2004–01June 2005.  
 The patient’s name, medical folder number and diagnosis were extracted from the 
admission book.  
 The admission and discharge book were also used to determine readmission of the 
identified subjects admitted with symptoms of acute exacerbation since on each 
admission patients are given a different folder number. 
Tygerberg and Karl Bremer Hospitals 
 At Tygerberg Hospital, the F1 medical emergency unit keep daily statistics with the 
patient’s personal details and diagnosis.  
 At Karl Bremer Hospital, the clerical department is able to create an admission and 
discharge report, with the patient’s name and diagnosis.  
 All patients admitted with symptoms of acute exacerbation within the period 01 June 
2004–01 June 2005 were identified from these statistical records.  
 
Medical folder 
 The researcher was able to identify patients by accessing the admission records kept 
at the different hospitals. 
 The folders of the identified subjects were requested from medical records once all 
potential candidates for the study were identified. 
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 These medical folders were searched to verify the diagnosis of COPD with acute 
exacerbation.  
 All previous admissions for an acute exacerbation requiring hospitalisation for a period 
of 12 months prior to the last admission closest to 01 June 2005 were recorded.  
  
3.10 Pilot study 
A pilot study was conducted two weeks prior to the main study at Karl Bremer and Tygerberg 
Hospital by the researcher. 
The objectives of the pilot study were to determine:  
 the accessibility of the medical folders, and 
 the validity of information gathered in the study. 
 
3.10.1 Pilot study procedure 
 Candidates were identified from the admission records of the selected hospitals. 
 The medical folders of the selected patients were searched to confirm the diagnosis of 
COPD, and only then were the patients placed on the pilot study database. 
 Only COPD patients hospitalised with symptoms of an acute exacerbation in the period 
02 June 2005–31June 2005 were included in the study. 
 All information pertaining to the first admission was entered on the patient data capture 
sheet 1 and medication data capture sheet 3 (see Addenda 1 and 3).  
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The following problems were identified: 
1. The accessibility of folders 
The ability to access the medical folders were limited by: outpatient clinics requiring 
patients’ medical folder for follow up appointments and therefore the folder was 
unavailable. Two requests to the medical records were made to obtain the folder, 
whereafter the patient was excluded from the study if the folder was unavailable, as the 
diagnosis of COPD could not be confirmed.  
2.  Missing folders 
When the medical records staff reported the folder untraceable or entirely lost the patient 
was excluded from the study as the diagnosis of COPD could not be confirmed. 
3. Missing information and illegible and missing microfilms 
The validity of information gathered in the study was hindered by missing information and 
illegible and missing microfilms, specifically at Tygerberg Hospital. 
 All missing information in the subjects folder were left blank on the data form as well as 
on the excel spreadsheet. 
 Illegible and missing microfilms: If the patients’ folders were obtained and diagnosis 
confirmed but the microfilms were incomplete or damaged, the patient was still 
included as a subject. However, only legible microfilms and documentation could be 
use in data extraction.  
4. The combination of data form two and three in to a single form facilitated effective and 
efficient data collection. The necessary changes were made and then combined into 
addendum two.  
 
 
 
http://scholar.sun.ac.za
 48
3.10.2 Procedure 
                       Obtain admission records at the selected hospitals 
 
 
                     Identify patients by symptoms (Refer to sections 2.4 and 2.7). 
 
 
                          
Private Hospital: n =86        Secondary Hospital =423         Tertiary Hospital =221        
 
 
Obtain and search medical folders to determine diagnosis of COPD with acute exacerbation. 
  
 
     Private Hospital =31         Secondary Hospital =119          Tertiary Hospital =28        
 
 
Search patient’s medical record retrospectively for a 12-month period prior to the last 
admission date (June 2005) for all acute exacerbations resulting in hospitalisation. 
 
                             Data extraction onto data capture forms   
 
 
                                   Data processing and analysis 
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3.11 Procedure of main study 
The main study, retrospectively, commenced on 01 June 2004. 
Patients were identified; data extracted and captured using the following methods by the 
researcher. 
 
3.11.1 Sampling procedure 
 
 Subjects were identified from the systems in place at the specified facilities where they 
were admitted. 
 The admission records of the medical wards from 1 June 2004 to 1 June 2005 were 
scrutinised 
 The folder number of all subjects admitted with at least one of the following symptoms 
was documented. Refer to section 2.7 
 The medical folder of all the identified subjects were requested from medical records at 
each of the facilities. 
 The researcher then accessed the records to identify subjects with a primary diagnosis 
of COPD.  
 Only the subjects that fulfilled above-mentioned criteria were finally included in the 
sample.  
 Only medical folders that were acquired from medical record department could be 
scrutinized to determine the inclusion of the subject as a candidate for the study.  
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3.11.2 Database compilation 
 The subject’s last admission for an acute exacerbation, closest to 01 June 2005, was 
used to compile the final database.  
 The medical folder of each subject was reviewed retrospectively for one year prior to 
the admission date closest to June 2005. 
 The name and file number of each subject was recorded on a separate patient 
confidentiality data sheet (see Addendum 4). All data were coded accordingly. 
 Addendum 4 was destroyed after all relevant documentation was obtained from the 
subject’s folder. 
 
3.11.3 Data extraction 
 All relevant data was extracted for each admission in the data collection period, 
Addenda A and B and was completed using the administrative information, physician’s 
notes and nursing progress notes.  
 Addendum C was completed using the prescription chart in the subject’s medical 
folder. 
 The patient’s name and folder number were recorded on Addendum D. 
 Weekly visits to all of the facilities were conducted, until all relevant data were captured 
from all subjects’ records for a period of four months by the researcher. 
 All information pertaining to repeat hospitalisations were documented on the 
readmission data capture sheet (see Addendum B) 
 All missing information, damaged and missing microfilms were treated and 
documented as absent information. 
http://scholar.sun.ac.za
 51
 Absent information and values were left blank on the data capture forms as well as 
when entering data on the computer.   
 As soon as all the data were captured on the data forms, the data were entered on the 
excel spreadsheet and thereafter submitted for statistical analysis. 
 Results were verified by an independent observer by extracting names from the 
sample and thereafter confirming accuracy of information entered from the data 
capture forms onto the Excel spreadsheet. 
 
3.12 Statistical analysis 
Summary statistics were generated and displayed using frequency tables, histograms, means 
and standard deviations. For comparison of ordinal/continuous variables between various 
different groups, one-way ANOVA was used. Assumptions for the ANOVA analyses were 
checked at all times. Categorical variables were compared using cross tabulation and the Chi-
square test. 
                                     
3.13  Ethical considerations 
 The research protocol was approved by the ethics committee of Stellenbosch 
University for approval: project number N05/07/118. 
 Permission was obtained from the medical superintendent and hospital director at the 
various hospitals for the research to be conducted at their facilities. Verbal consent 
was obtained at Panorama Medi-Clinic, Karl Bremer and Tygerberg both gave written 
consent. (See Addendum E and F)   
 As this is a retrospective study no written consent was obtained from the patients. 
http://scholar.sun.ac.za
 52
 As this was an observational study, it would by no means affect the current and 
prospective medical management of the relevant patients. 
 The information obtained will remain strictly confidential by delegating a numerical 
code to the patient’s identity and will store in a secure environment.  
 A data sheet (see Addendum D) was created with the patients name and delegated 
numerical code, to enable the researcher access the patient’s medical folder. Only the 
researcher has access to it. Once all the relevant data were extracted from the medical 
folder, the data sheet (see Addendum D) will be were destroyed. 
 The results are available to all the hospitals where the research was conducted, with 
no reference to patients’ identities. 
 During the course of the research project consent was not obtained from Louis Leipoldt 
Medi-Clinic, and therefore no data were collected at their facility. (Extensive attempts 
by means of telephonic contact to Medi-Clinic research personnel as well as 
forwarding the research proposal to their legal department to obtain permission to 
conduct the research unfortunately did not render any results.) 
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Chapter 4 
 
Results 
 
4.1 Introduction  
In this chapter the results will be presented and discussed as follows. Firstly, a description of 
the total population with respect to the sample demographics followed by a description of the 
medical conditions in relation to admission one, admissions two or three and more than three 
admissions will be given. Selected outcomes of the 178 subjects will then be described with 
respect to the admission frequency and length of hospital stay. Finally, factors influencing the 
outcomes of the 178 subjects will described with respect to hospital readmission, age and 
readmission, gender and readmission, co morbidities and readmission and, finally, LTOT and 
readmission.  
 
4.2 Sample demographics  
The demographics of the 178 subjects obtained from the tertiary and secondary state and one 
private hospital were the following: age, co morbidities, smoking status and social status. 
These are expanded on in sections 4.2.1– 4.2.4. 
 
In the period 01June 2004 –01June 2005, 178 subjects were identified at the two state and 
one private hospital in the Cape Metropolitan area (see Section 4.5.1). The majority of 
subjects had one or more co morbidity (79%) while only 21% of subjects had no co morbidity. 
All of the subjects had a positive smoking history: 66% were ex-smokers and 34% continued 
to smoke. The secondary state hospital had the majority of subject admissions n=119 (67%), 
the private hospital n=31 (17%), and the tertiary hospital n=28 (16%).  See Table 4.1 
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Table 4.1 Characteristics of the subjects 
DEMOGRAPHICS TOTAL 
Number of subjects 178 
Age (years) (Mean:SD) 63 (11.73) 
Gender (male : female) 103 : 75 
Number of co morbidities (yes : 
no) 
140 : 38 
History of smoking 
Currently smoking (no : yes) 
178 (100%) 
117 : 61 
Social status (%)  
 Employed                          
 Unemployed  
 Receiving disability 
grant 
 Pensioner  
 
11 
20 
10 
58 
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4.2.1 Age of the subjects   
The mean age of this population (n=178) was 63 (SD 11.73). There were n= 51(29%) 
subjects between the ages of 65 and 75. Only a few subjects were older than 75. Fifty-six per 
cent of subjects were younger than 65 years of age, while one subject was as young as 30 on 
entry into the study. The ages of the subjects on entry into the study are presented graphically 
in Figure 4.1.  
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Figure 4.1   Age of subjects on entry into the study  
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4.2.2 Co morbidities of the subjects 
The majority of subjects in this population had one or more co morbidities; only 21% of the 
subjects had no co morbidity. Seventy-nine percent had co morbidities recorded. The co 
morbidities recorded were based on the most frequently observed co morbidities in COPD 
subjects and these included the following: diabetes mellitus (DM), ischaemic heart disease 
(IHD), congestive cardiac failure (CCF), stroke, Tuberculosis (TB), hypertension (HPT), cor 
pulmonale, cancer and asthma.  See Figure 4.2 below depicts the co morbidities observed in 
the subjects.  
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Figure 4.2   Associated co morbidities of subjects  
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4.2.3 Smoking status of the subjects 
In the present sample, only ex-smokers and subjects who continued to smoke were identified. 
Hence, all 178 subjects had a positive smoking history. The number of ex-smokers (n=117) 
was significantly higher than the number of current smokers (n=61) in the current sample. See 
Figure 4.3 below. 
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Figure 4.3 Smoking status 
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4.2.4 Social status of the subjects 
Figure 4.4 depicts the employment status of subjects on their first admission. The largest 
percentage of the sample comprised predominantly pensioners, individuals 60 years and 
older or persons on early pension. 
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Figure 4.4 Social status of the subjects on entry into the study 
 
4.3 Clinical presentation of the subjects   
No comprehensive analysis could be obtained to establish the medical status of subjects on 
admission and discharge as data concerning the medical status of the patient were not in the 
medical folder, there for objective #2 (refer to Section 3.2.1) could not be accomplished. All 
relevant clinical data relating to the clinical presentation of the patients were collected where 
available: pulse, respiratory rate, blood pressure, temperature, oxygen saturation, blood 
gases and lung function. The clinical presentation on admission and discharge will be 
described as obtained for the 178 subjects in relation to admission 1, admissions 2 or 3, and 
> 3 admissions in respect of the available vital signs.  
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4.3.1 Vital signs 
At all three admissions subject had the following vital signs on admission:  
1 Subjects with one admission presented with an elevated mean pulse of 101 
beats/min (60–90 normal) and a mean respiratory rate of 26 breaths/min (12–18 
normal)  
2 Subjects with 2–3 admissions presented with a pulse mean of 106 beats/minute 
and a mean respiratory rate of 28 breaths/min. 
3 Subjects with > 3 admissions presented with a mean pulse of 120 beats/min and a 
mean respiratory rate of 32 breaths/min.  
 
Both respiratory and pulse rates normalised towards discharge for subjects with fewer 
than three admissions, however pulse and respiratory values of subjects that where 
admitted more than three times remained elevated at discharge.  
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Missing information 
The following clinical variables had less than 10% missing values: smoking, pulse on 
admission and discharge, blood pressure on admission and discharge, co morbidities, 
temperature on admission, reason for admission, gender, age, social history, ambulant or 
non-ambulant, LTOT and hospital oxygen. Table 4.2 displays 10-99% of missing values as 
found during the data extracted period for the 338 hospitalisations.  
 
 
Table 4.2   Missing data  
                           number missing % missing 
PaO2 discharge (D/C)                  336 99 
PaCO2 D/C 336 99 
pH D/C 336 99 
O2 saturation D/C 336 99 
# times TB 330 98 
Height 319 94 
FEV1 303 90 
FVC 303 90 
FEV1/FVC 303 90 
Dyspnoea admission (adm.) 282 83 
PaO2 281 83 
PaCO2 281 83 
pH 281 83 
Baseline dyspnoea 251 74 
O2 saturation 247 73 
Weight 228 67 
Respiratory rate D/C 198 59 
Respiratory rate adm. 124 37 
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4.4 Selected outcomes 
Admission frequency and the length of stay of subjects hospitalised with acute exacerbation 
of COPD were investigated.  Each of the subjects was reviewed over a 12-month period. The 
selected outcomes of the 178 subjects are described in respect of admission frequency and 
length of hospital stay (sections 4.4.1 and 4.4.2). 
 
4.4.1 Admission frequency 
Of the n=178 admissions in the current study, 100 subjects were admitted once and 78 
subjects (44%) were admitted two or more times in the 12-month follow-up period. The 
majority of the 78 subjects had a least two admissions (25%), with four subjects having as 
many as eight readmissions in the preceding 12-month period (see Figure 4.5). 
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Figure 4.5 Admission frequency of the subjects as observed in the 12-month follow up 
period of the study 
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4.4.2 Length of stay (LOS) 
The mean LOS per subject was 5, 67 (± 6.55) days per admission. There were no differences 
observed amongst the three hospitals in respect of the LOS. However, subjects admitted 
once within the study period stayed the longest, with a mean of 6.2 days per admission. 
Those admitted two or three times stayed on average 5.5 days per admission and subjects 
who were admitted more than three times had an average stay of six days in hospital.  
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Figure 4.6   Length of stay (days in hospital) 
 
4.5 Factors influencing outcomes 
The factors that influenced the outcomes of the 178 subjects are now described as follow:  
hospital readmission, age and readmission, gender and readmission and co morbidities and 
readmission in respect of admission1, admission 2 and ≥ 3 admissions. LTOT and 
readmission will be described in relation to admission1, admission 2 or 3 and > 3 admissions 
(see sections 4.5.1– 4.5.5). 
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4.5.1 Hospital readmission 
The 178 rendered 338 hospital readmissions, however those admitted more than twice (n=78) 
contributed to the majority of readmissions (n=238). Although the secondary hospital had the 
majority of subject admissions, subjects admitted to the tertiary  hospital were more likely to 
be readmitted mean 2.3 compared with <2 at the secondary hospital. However this was not 
significant (p=0.49).   Figure 4.7 depict the readmissions as observed at the three hospitals. 
 
 
Figure 4.7 Readmission at the three hospitals  
 
4.5.2 Age and readmission 
Although subjects with one admission were younger (mean age 62) compared to subjects 
with two and more admissions (mean age 64 years and older), there was no correlation 
between age and the risk for readmission in the current sample (p=0.5). Subjects at the 
private hospital were slightly older (mean age of 65 years) than individuals at the secondary 
and tertiary hospital (mean age 63 and 62 years respectively). However, being older and 
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hospitalised at the private hospital was not associated with an increased risk of readmission 
(p= 0.28) 
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Figure 4.8 Relationship of age and frequency of admissions 
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Figure 4.9 Age of the subjects as admitted at the three hospitals  
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4.5.3 Gender and readmission 
On first admission there were more males than females. This however proceeded to equalise, 
with minimal differences seen between subjects with two and more admissions. There were 
however more females than males in subjects with ≥ 3 admissions. Using statistical 
procedure, the chi-square test, a significant trend could be observed (refer to Figure 4.1), 
indicating an increased risk for readmission in female subjects who required ≥3 admissions 
(p= 0.16).  
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Figure 4.10 Gender distribution of the subjects at each of the admission periods 
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4.5.4 Co morbidities and readmission 
Subjects with more than three admissions had at least two co morbidities compared to those 
with ≤3 admissions who had only one co morbidity. Subjects with two or more co morbidities 
had an increase risk for readmission (p=0.02). However, subjects with congestive cardiac 
failure were specifically more at risk for three or more readmissions (p=0.01).  
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Figure 4.11 Number of co morbidities at each admission period 
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Figure 4.12   Number of subjects with co morbidities at each admission period 
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4.5.5 Long-term oxygen therapy (LTOT) and readmission 
Only 16 subjects in this sample (n=178) had oxygen therapy available at home. The risk of 
readmission was highest in the group with no LTOT available to them (p=0.017) (see Figure 
4.13). 
 
Home O2
nu
m
be
r o
f s
ub
je
ct
s
# admissions2: 1 admission
no at least once
0
20
40
60
80
100
# admissions2: 2 or 3 admissions
no at least once
# admissions2: 4 or more admissions
no at least once
0
20
40
60
80
100
94%
6%
93%
7%
71%
29%
 
Figure 4.13 The number of subjects with LTOT at each of the admission periods 
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Chapter 5 
 
Discussion 
 
5.1 Introduction  
This chapter will discuss the results obtained after completion of the data compilation 
phase. As mentioned at the outset (Section 3.1.2), the objectives of this study were to 
describe the profile of COPD patients hospitalised with acute exacerbation in the Cape 
Metropolitan area, to describe the medical condition of the patient on admission and 
discharge, as well as to describe the readmission and length of stay of these patients. 
Factors that were found to influence the characteristics and selected outcomes of the 
current study population are now discussed accordingly. 
 
Except for the age variation, patients admitted with acute exacerbation in this study 
presented with a similar profile to patients in developed countries with regard to co 
morbidities, gender and smoking history (Franciosi et al., 2006; Garcia-Aymerich et al., 
2001; Garcia-Aymerich et al., 2003: Groenewegen et al., 2003: Miravitlles et al., 2000; Sin 
et al., 2000). 
 
5.2 Demographics of the sample  
The demographic profile of this study population (n=178) was predominantly male, with a 
mean age of 63 (11.73), presenting with evidence of one or more co morbid diseases, and 
a positive history of smoking. In this section the demographics of the study population will 
be discussed under the following headings: age, gender, social history, co morbidities and 
smoking behaviour (see sections 5.2.1–5.2.5). 
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5.2.1 Age 
The mean age of the current subjects hospitalised with acute exacerbation was 63 
(±11.73) yrs, varying from 30–95. This is in contrast to studies carried out in countries as 
United States and Europe here the mean age for subjects requiring hospital admission for 
acute exacerbation was >65 (Franciosi et al., 2006; Miravitlles, et al., 2000; Seemungal et 
al., 1998). These studies were performed in industrialised countries where the 
identification of COPD occurs at an earlier stage due to better health systems and 
increases in life expectancy are evident. In those countries the appropriate medical 
interventions and lifestyle changes occur at an earlier stage of disease, which can 
contribute to the differences in age observed in the current study and the above-mentioned 
studies (www.lungusa.org/site/pp.asp, accessed 17 March 2005; 
www.euro.who.int/ehr2005, accessed 06 July 2007).  
 
Although the current South African study data were obtained from both first and third world 
health environments the majority of South Africans depend on the public health service. 
After an extensive search of electronic data bases the author was unable to identify 
comparable data of patients hospitalised with acute exacerbation in a third world 
environment. 
 
The major concern identified in the current study was the large proportion (56 %) of 
subjects younger than 65 years of age admitted at least once in the study period with an 
acute exacerbation. Only 29 % of subjects in the current study were 65–75 years of age. 
This is in contrast with studies carried out in developed countries, where patients admitted 
with acute exacerbation were generally older, namely 65–75 years of age (Garcia-
Aymerich et al., 2003; Groenewegen et al., 2003, Miravitlles et al., 2000).  
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The significant variation in age (30–95) amongst the current subjects admitted with acute 
exacerbation can possibly be attributed to the increase in exposure to tobacco smoke. In 
South Africa light and heavy smoking is highest in the age group 35–44 yrs for males and 
females, which substantiates the increase in smoking behaviour observed amongst 
especially the younger population worldwide (Bradshaw et al., 1996; www.who.int/whr, 
accessed 02.06.2007). Indoor pollution resulting from domestic use in sub-Saharan Africa 
could expose individuals at a much younger age, especially females, to harmful levels of 
pollution and increase the risk profile of these subjects (GOLD, 2000). Air pollution has 
been recognised as contributing to 20% of all COPD diagnosed worldwide placing further 
emphasis on this environmental risk factor (www.who.int/whr, accessed 02.06.2007). 
 
Episodes of acute exacerbation are not uncommon in patients presenting with COPD. It is 
considered prevalent among patients with moderate to severe COPD and is associated 
with increased frequency and disease severity (Burge et al., 2003; Garcia-Aymerich et al., 
2001). The presence and severity of symptoms have also been associated with the extent 
of exposure to risk factors contributing to COPD. Thus susceptible individuals with a long 
and intensive history of smoking will suffer more with acute exacerbation compared to 
individuals who smoke less or who stop smoking (Franciosi et al., 2006). 
 
It is especially respiratory infections, both viral and bacterial, that are associated with acute 
exacerbation. Such infections are common in both young and old individuals, but 
especially in patients with COPD. Patients with COPD are predisposed to respiratory 
infections due to the cycle of chronic inflammation of the bronchial tree causing pooling of 
mucus clogging up the airways and leading to poor cilia action caused by irritants like 
tobacco smoke or other noxious gases (www.goldcopd.com/, accessed 21.12. 2007 ; 
Pistelli et al., 2003). Patients have difficulty clearing secretions effectively and the 
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continuous exposure to risk factors, either air or occupational pollution, and cigarette 
smoke, will aggravate the symptoms of dyspnoea, wheezing and secretions, and can 
influence admission for acute exacerbation (Pistelli et al., 2003).  
 
The data in this study were obtained from both first and third world environments and the 
age differences between subjects admitted at the three hospitals were not significant. This 
suggests that all sectors of the South African society are exposed to similar types of risk 
factors. Inevitably some variations amongst the affluent and non-affluent communities exist 
and contribute to differences in risk profiles of the various groups. Age in itself does not 
appear to contribute to acute exacerbation. It is the culmination of exposure to risk factors 
resulting in the damage to the lung tissue that is most important. 
  
5.2.2 Gender of the study sample  
The gender composition in the current study demonstrated more male (103) than female 
(75) subjects admitted with acute exacerbation, in a ratio of 1:3:1. These results are similar 
to studies in developed countries, demonstrating the increasing prevalence of COPD 
amongst females. The increased tobacco usage amongst females observed in both 
developed and developing countries contributes to the prevalence of COPD amongst 
susceptible women (www.goldcopd.com/, accessed 21.12. 2007).  
 
The reasons for females developing severe COPD that can influence admission can be 
attributed to differences in the decline of FEV1 associated with the response to tobacco 
smoke inhalation as well as their genetic predisposition to develop more severe COPD 
with a similar smoking history (de Torres et al., 2007; Prescott et al., 1997). 
Silverman et al. (2000) have reported that females who smoke have a significantly 
increased risk of developing severe COPD compared to males. The decline in FEV1 of 
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smoking females compared to smoking male subjects was significantly greater, indicating 
that females may suffer more from the adverse affects of tobacco smoke (with a similar 
pack-year history) than their male counterparts (Prescott et al., 1997). However, further 
studies need to be conducted to establish the exact reasons for this discrepancy.  
 
The development of COPD in women has also been associated with anatomical 
differences between males and females. A recent study published reported that  females 
have anatomically smaller lumen sizes with disproportionate thicker airway walls, less 
extensive emphysema, smaller hole sizes and less peripheral involvement than males, 
although they generally had a shorter smoking history compared to the male subjects 
(Martinez et al., 2007). These differences also relate to the subjective experience of the 
disease that has been noted to be different between males and females.  
 
For the same level of airway obstruction and a similar smoking history, females 
experienced increased dyspnoea and walked less on the 6-minute walk test (Torres et al., 
2007). As the criteria for admission for an acute exacerbation are not always clear; a 
patient’s subjective experience of a symptom like dyspnoea could influence the admission 
rate. 
 
5.2.3 Social history  
The majority of patients in this study population were pensioners (58%). This is not 
surprising as 59% of patients were older than 60, with 60 being the cut-off date for 
retirement for females and 65 for males in South Africa. 
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What is however disconcerting is that of the remaining 41% of the study population only 
11% were employed, with 10% disability grant recipients. This could be due to the high 
unemployment evident in the South African population today. This study did not explore 
the reasons for disability grants but the discrepancy could possibly be related to a 
decrease quality of life associated with an increased number of admissions (Puhan et al., 
2005). The fact that in this study there is evidence of a younger population suffering from 
COPD could impact on the burden of this disease on the economical viable sector of the 
population. Further studies are needed to quantify this burden and explore the modifiable 
exposures contributing to this result. 
 
5.2.4 Co morbidities 
Co morbidities found in the present study of subjects admitted with acute exacerbation 
were comparable to those observed in international studies. The majority of the current 
178 subjects recorded one or more co morbid diseases; only 21 % of subjects recorded no 
known co morbidities (Connors et al., 1996; González et al., 2004).  
 
One of the reasons proposed for the increase in especially chronic disease in the 
developing countries is the influence of developed countries and the impact of rapid 
industrialisation (Bradshaw and Steyn, 2001).  
 
Chronic diseases are a significant cause of disability and deaths in both the developing 
world and the developed world although the prevalence of certain diseases may be 
country specific (www.who Tuberculosis.htm, accessed 17.03.2005). Chronic diseases are 
lifestyle diseases that share similar risk factors, including poor diet, lack of exercise and 
increased exposure to tobacco smoke. Exposure to these risk factors happens over a 
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period of time and the symptoms of these chronic diseases are not immediately evident 
(Bradshaw and Steyn, 2001).  
 
The risk factors mentioned above also contribute to the development of other lifestyle 
diseases such as specific cancers, heart disease and respiratory conditions. Specifically in 
South Africa, the rapid transformation has been noted to result in changes in lifestyle in all 
sectors of the South African society, but particularly in the underprivileged groups. This 
can potentially contribute to an increased prevalence of chronic diseases as COPD 
amongst the poorer communities (Bradshaw and Steyn, 2001). As the poorer communities 
are exposed to similar social transformations that have occurred in the affluent 
communities they will also be exposed to similar health problems.  
 
The co morbid diseases observed in patients hospitalised with acute exacerbation in the 
current study are very similar to those studied in developed countries (Bradshaw and 
Steyn, 2001; Pistelli et al., 2003). However, the similarities may be attributed to influence 
from developed countries that should not be underestimated, and which require further 
attention. In the South African context the expectation would be to observe different trends 
and predominance of certain disease above others due to the complexities of a multi 
cultural society each with different habits, lifestyles and diet. 
 
5.2.5 Smoking behaviour 
In the present study all the subjects had a history of smoking either current or past.  
Smoking is a well established risk factor for COPD (www.goldcopd.com/, accessed 21.12. 
2007).  
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COPD has predominantly been recognised to be prevalent in males due to their historical 
smoking behaviour but increased tobacco smoking is now found in females as well as 
young individuals and this may be one reason for the positive smoking history in the 
current study (American Thoracic Society, 2006; www.goldcopd.com/, accessed 
21.12.2007; www.who.int/whr, accessed 02.06.2007).  
 
In the Lung Health Study the decline in FEV1 was slightly different for males and females 
who smoked; FEV1 decline for males was greater (30.2 ml/yr) compared to females (21.5 
ml/yr) (Anthonisen, et al., 2002). Although this difference was not significant when the 
FEV1 was expressed as a percentage of the predicted normal value, it highlights the 
differences in response to tobacco smoke inhalation amongst individuals.  
 
The significance of tobacco smoke is the effects of chronic inflammation, breakdown of 
lung elastin and mucus hypersecretion within the lungs. COPD does not occur in all 
smokers but 15–20% of all smokers eventually develop symptomatic signs of the disease. 
The reason for only a minority of smokers developing symptomatic COPD can be due to 
susceptibility of the individual to develop the disease. When individuals, prone either 
through genetic influences, history of respiratory infections in childhood or asthma, start to 
smoke the disease process is initiated. Initially the disease start at a low intensity but 
eventually as the risk exposure continues development of the disease advances.  
 
5.3. Medical condition of the study subjects 
Due to insufficient data, objective #2, the aim of which was to describe the medical 
condition of subjects on admission and discharged when hospitalised with acute 
exacerbation, could not be accomplished.  
Missing data 
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Significant in this study was the large percentage of missing values; these ranged from 0 
% to 99 %. Especially blood gases on admission and discharge, spirometry, weight and 
height had more than 60 % missing values. Internationally, criteria for hospital admission 
are determined by certain outcome measures such as severity of symptoms, quality of life, 
physiological factors (blood gases), frequency of admission and economic cost (Jr 
Carmargo., 2002; MacNee, 2003).  
 
The clinical data in respect of vital signs, lung function and blood gases are important 
clinical factors as they influence the management of the patient. It establishes the severity 
of the condition on admission and assists with the decision whether to stabilise the patient 
in the emergency unit or admit the patient to the ward. The records also serve as a 
baseline for future admissions as the patient may deteriorate with a decline in lung 
function, and evidence of worsening blood gases can indicate significant deterioration of 
respiratory system and may require change in medication or the prescription of LTOT.  
 
Reasons for data not being available could include staff shortage, poorly equipped units, 
equipment malfunction or equipment being unavailable owing to its being repaired, and a 
variety of other reasons, including financial as well as staff redeployment to busier areas in 
the hospital. There is insufficient information to ascertain if any admission and discharge 
criteria exist for patients hospitalised with acute exacerbation at the involved facilities.    
 
5.4 Selected outcomes  
In the current study n=178 subjects resulted in 338 hospitalisation throughout the three 
hospitals with 78 of the subjects resulting in two or more admissions. The majority of 
hospitalisations (238) were as result of the 78 subjects requiring two or more admissions. 
There was no significant difference in the profile of this small group of patients (n=78) 
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presenting in either the private or the state institutions. The factors investigated included, 
the age, co morbidities, smoking history, social history, and gender. This could be because 
of the small number of patients readmitted making it difficult to identify differences in the 
profile or alternatively that contrary to common belief the patients receive similar care in 
these two diverse health care systems.  
 
The small number of patients (n=78) identified in this study as being readmitted more than 
once, concurs with research in developed countries indicating increased health care 
utilisation by a small proportion of patients (Stanford et al., 2005; Strassels et al., 2001). 
Recorded admission frequencies of up to eight episodes for the 78 subjects were noted 
during the follow-up period. Although the majority of the 78 subjects (25 %) in the current 
study were only readmitted twice, four subjects (2 %) required eight readmissions in the 
study period.  
 
In the following section the selected outcomes of the subjects will be discussed with 
reference to the variables that were significantly associated with the selected outcomes: co 
morbidities and readmission, long-term oxygen therapy (LTOT) and readmission, and 
length of stay (LOS) and readmission (see sections 5.4.1–5.4.3). 
 
5.4.1 Co morbidities and readmission  
In the current study the presence of two or more co morbidities was associated with an 
increased risk of readmission of up to three or more times (p=0.02). Specifically, 
congestive cardiac failure (p=0.01) was significantly associated with an increased risk of 
increased admissions. These results are comparable to other studies that showed an 
increased presence of co morbidities with patients requiring hospital admission and the 
presence of significant cardiac diseases increasing the risk for readmission. In a study by 
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Connors et al. (1996) cor pulmonale and congestive cardiac failure were independent risk 
factors associated with poor survival after admission for acute exacerbation.  
 
González et al. (2004) also reported cor pulmonale to be one of the independent risk 
factors for hospitalisation with moderate to severe COPD. All the subjects in the study 
were male and this hence limited the results to male subjects only, whereas the current 
study was conducted with no gender specification.  
 
A reason for the presence of significant cardiac disease influencing admission may be the 
extent of lung damage attributed to the severity of the disease. An increase in pulmonary 
artery pressure and right ventricular failure may ensue as a result of the severity of 
destruction of the pulmonary vascular bed as well as the vasoconstriction of the arterioles, 
causing hypoxia (Kessler et al., 1999). Heart failure in COPD is associated with a 
significant decrease in lung function, which can possibly be due to infection (Pistelli et al., 
2003). Infections of the tracheobronchial tree are thought to be the main cause of acute 
exacerbations as they are commonly found in those patients admitted with acute 
exacerbation, although in a significant proportion of patients the cause of acute 
exacerbation remains unidentified (www.goldcopd.com/, accessed 21.12. 2007)  
 
5.4.2 Long term oxygen therapy and readmission  
In the current study, subjects admitted for acute exacerbation without long-term oxygen 
therapy demonstrated an increased risk of admission (p=0.01). This result is similar to 
those of the study Garcia-Aymerich et al. (2001) who found that the under-prescription of 
LTOT was one of the independent associated factors for an increased risk of readmission 
with acute exacerbation.   
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The decision to provide LTOT for individuals is recommended in the very severe stage of 
COPD with the FEV1 < 30 % (percentage predicted normal value), oxygen saturation 
below 90% or PaO2 < 7.3 kPa.  A possible reason proposed by Garcia-Aymerich et al. 
(2001) for the under-prescription of LTOT is attributed to patients still continuing to smoke. 
However this argument is not relevant in the current study as 66% (117) of the study 
subjects were ex-smokers during the study period.  
 
A plausible reason might be budget constraints as the availability of health resources are 
dictated by priority diseases as the HIV/AIDS epidemic and related conditions. The main 
emphasis of the health sector will focus on those diseases but may unfortunately result in 
the neglect of chronic disease as COPD. Second, the decision to provide LTOT requires 
knowledge of the severity of disease by performing required lung function test by means of 
spirometry, but this was not recorded in the majority of subjects’ medical records. 
Therefore, another reason for the under-prescription of LTOT can be attributed to a lack of 
knowledge regarding the existing severity of lung disease to be able to assess the need for 
oxygen at home. In the South African context the impact of providing LTOT at primary 
healthcare centers on readmission rates could be investigated. 
 
5.4.3 Length of stay and readmission 
The number of days spent in hospital (LOS) in the current study were in line with data from 
developed countries and no significant differences were observed amongst the patients at 
admission 1, admissions 2 or 3 and >3 admissions. Even patients with > 3 admissions did 
not result in a significant increase in the number of days in hospital. The mean number of 
days in hospital was 5.67 per admission, which is similar to the results of studies in 
developed countries (Cotton et al., 2000; Sin et al., 2000). The length of stay may vary 
according to the criteria used for hospital admission and discharge as observed in the 
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studies by Connors et al. (1996) and Sullivan et al. (2000). The median number of days 
was 9–10 in the two studies but this can be attributed to differences in health practices of 
various countries or extenuating circumstances influencing admission.  
 
The occurrence of eight readmission frequencies may be considered in the light of the 
argument proposed by Burge et al. (2003), namely that readmission within 14 days may 
actually be a relapse and not a new episode of acute exacerbation. In the light of the 
proposed theory, these patients may actually have required and would have benefited 
from a longer hospitalisation period, and this may ultimately influence readmission 
frequency. However, no definitive studies have been carried out exist to determine the 
exact LOS for patients admitted with acute exacerbation as they may have associated 
conditions influencing their hospitalisation (Cotton et al., 2000).  
 
Patients hospitalised with acute exacerbation takes longer to recover even when receiving 
optimal medical care and eventually struggle with the simplest tasks involving activities of 
daily living (Fan et al., 2002). The repeat cycle of readmission further compromises their 
quality of life (Man et al., 2004, Reis et al., 2007).  
 
Benefits of increase in exercise ability, decrease fatigue and dyspnoea were demonstrated 
when patients enrolled in a pulmonary rehabilitation programme (Güell et al., 2000; Puhan 
et al., 2005). Specifically post acute exacerbation these benefits were observed compared 
with patients receiving standard medical care that does not include pulmonary 
rehabilitation (Güell et al., 2000; Jenkins et al., 2001; Man et al., 2004). In the randomised 
controlled trail of Man et al. (2004) they observed a reduction in hospital admission, days 
spent in hospital and increase in exercise ability after patients enrolled in a pulmonary 
rehabilitation programme following hospitalisation for an acute exacerbation. Patients also 
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experience fewer days in hospital when readmitted and reduction in exacerbation, and 
therefore a decrease in cost associated with hospitalisation (Reis et al., 2007).  
 
In summary from the demographics and outcomes observed in this study it is clear that 
many of the lifestyle diseases observed amongst COPD patients such as high blood 
pressure, cardiovascular conditions and diabetes mellitus can benefit from a 
comprehensive pulmonary rehabilitation programme (Reis et al., 2007).  
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Chapter 6 
 
6.1 Conclusion  
The aim of the study was to describe the age, gender, social history, co morbidities and 
smoking history as well as the readmission frequency and length of stay of COPD patients 
hospitalised with acute exacerbation in the Cape Metropolitan area. Although patients in 
this study were admitted at three hospitals comprising of both public and private 
institutions, there were no significant differences either the profile or the outcomes 
between the hospitals.  
 
Patients admitted with acute exacerbation at these hospitals demonstrated an age 
variation of between 30 to 95 years, mostly male although the male to female ratio were 
very similar. Very few active smokers were identified as the sample consisted 
predominantly of ex–smokers. Co morbidities were frequently observed in the sample 
especially high blood pressure, tuberculosis, congestive cardiac failure and cor pulmonale. 
The mean length of stay in hospital was 5.67 (±6.55) days.  
 
Of the n=178, 100 (56 %) of the patients were admitted once and n=78 (44 %) admitted 
two or more times in the study year. Although less than 50 % of patients were admitted 
two or more times they experience up to eight admissions during the 12-month study 
period due to acute exacerbation. The n=178 patients resulted in 338 hospital admissions. 
As can be seen from the results of the study majority of patients were under the age of 65 
years, the work able component of the population. And although less than 50 % of patients 
were readmitted this has substantial economic impact for these individuals who are 
employed in respect of lost income and to the country in loss of productivity.  
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Pulmonary rehabilitation programmes have been associated with decrease in readmission 
of COPD patients with episodes of exacerbation. The fact that less than 50 % of this 
sample was admitted more than twice and some patients up to eight times leads to the 
question of the availability and utilization of pulmonary rehabilitation programmes.   
 
In the current study factors that influenced readmission were a history of three or more 
admissions in the study year, two or more co morbid diseases, and the presence of 
congestive cardiac failure and the lack of LTOT. Another factor that may also contribute to 
the risk of readmission and deserve further consideration is female gender, but larger 
studies are required to investigate this factor. 
 
A challenging limitation of the study was the poor record keeping observed in respect of 
the missing data as obtained from the medical folders and this affected the results 
obtained.  The poor documentation reported in this study is in contras to the GOLD 
guidelines as endorsed by the South African Thoracic Society which sets standards for the 
treatment, management and hospitalisation of patients with COPD and acute 
exacerbation. The implementation of these standards is dependent on reliable medical 
records to manage the patients’ condition (Bateman et al., 2004; www.goldcopd.com/, 
accessed 21.12.2007).  
 
In summary patients hospitalised with acute exacerbation at the hospitals where the study 
were conducted exhibits similar characteristics and outcomes as found in developed 
countries (González et al., 2004; Kessler et al., 1999). Pulmonary rehabilitation has proven 
benefits in developed countries and it is strongly recommended that a pulmonary 
rehabilitation be commenced in the northern suburbs of the Cape Metropole. The initial 
programme could be initiated at the secondary hospital as it was recorded to have the 
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highest admission rate amongst the three hospitals. The feasibility of incorporating such a 
programme into either the work place or home needs to be investigated as many of the 
patients hospitalised were young enough to be employable. The cost benefit of the 
implementation of pulmonary rehabilitation program needs to be investigated. As can be 
concluded from the study results the socioeconomic burden is considerable even in this 
small proportion of patients that required frequent admission and necessitates an urgent 
intervention in terms of a pulmonary rehabilitation programme. 
 
6.2 Limitations  
The current study has several limitations and this will be dealt with accordingly.  
 
6.2.1 Burden of disease 
As can be seen from the results of the study majority of patients were under the age of 65 
years, the work able component of the population. And although less than 50 % of patients 
were readmitted this has substantial economic impact for these individuals who are 
employed in respect of lost income and to the country in loss of productivity. Studies 
looking at the impact of hospitalisation on the individual and the extended family and what 
preventative measures can be taken needs further consideration.  
 
6.2.2 Patient identification 
Although all efforts were made to include all COPD patients hospitalised with acute 
exacerbation the ability to obtain all the medical folders for screening was a significant 
limiting factor. Following the pilot study the decision was made to exclude patients from the 
study when after two requests to the medical record department for a medical folder 
produced no results. The reason for this decision was that the diagnosis of acute 
exacerbation could not be verified without a medical record, and the reality of the time 
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constraints within which the study had to be completed.  This may have led to the 
exclusion of a number of patients and thus contributed to the low number of patients in the 
current study. However, the decision would not have favoured one hospital to another and 
thus the picture of the burden to all sectors of the health service provided in the Northern 
Suburbs as portrayed in this study would be realistic.   
 
6.2.3 Missing information 
The lack of record keeping observed in the current study as documented by the large 
percentage missing values resulted in the failure to describe the medical condition on 
admission and discharge of the patients admitted with acute exacerbation. The 
requirement of hospitalisation reflects the level of illness of patients as the patient cannot 
be cared for at home as well as assisting in the planning of immediate and future 
interventions but this could not be determined in the current study. However the obvious 
deduction would be that patients were fairly ill as a number of patients required up to eight 
admissions in the 12-month study period. Alternatively patients were discharged 
prematurely because of the shortage of beds which will inevitably influence both admission 
and discharge criteria as proposed by South African Thoracic Society (Bateman et al., 
2004, www.goldcopd.com/, accessed 21.12.2007)  
 
Due to the retrospective study design only information available in the medical folder could 
be used in data extraction. Future studies aimed at describing the profile of COPD patients 
hospitalised with acute exacerbation should preferably be of a prospective design. This 
could possible facilitate the process of data collection.   
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6.2.4 Hospitalisation 
The subjective experience of increase in wheezing, dyspnoea and sputum production 
associated with acute exacerbation inevitably allows for clinical interpretation of the 
severity of symptoms. This will influence hospital admission due to variation that will exist 
in clinical judgement. That is why SA recommendations include criteria for admission. 
Other factors that may influence hospital admission between the state and private 
hospitals are availability of beds and staff at the state hospitals against the paying client at 
the private hospital. These are economic factors and regrettably cannot be controlled. 
 
Although the strict criteria were set and adhered to by the researcher based on all the 
requirements for hospitalisation from extensive literature search, the retrospective study 
design may allow for the some imprecision as the primary diagnosis of COPD is based on 
medical folder information and not substantiate by availability of lung function values. 
Unfortunately a few patients may have been included in the study that may have not been 
suffering with acute exacerbation but required hospitalisation for other illnesses as COPD 
is a subset of obstructive lung disease which includes cystic fibrosis, bronchiectasis and 
asthma.  
 
The other limitation in the current study is that the present data only reflects actual hospital 
ward admissions and not the emergency ward admissions that may presumably be much 
higher. Although this was a specific decision of the current study as the significance of 
hospitalisation with acute exacerbation is the associated with disease severity and 
decrease quality of life experience as result of readmission. Especially in the public 
hospitals the patients may not be hospitalised as frequently as in the private although no 
significant differences were seen as they appear to have similar admission frequency 
statistically. A study on the visitation of the emergency departments by patients with acute 
http://scholar.sun.ac.za
 87
exacerbation would be beneficial in determining whether patients use this service 
frequently and why or do they wait until very ill and subsequent need hospitalisation.  
 
The availability and access of pulmonary rehabilitation programmes in the northern 
suburbs were not investigated in this study as this would provide insight into the subjective 
experience of the disease process on the patient. The results of a pulmonary rehabilitation 
programme may decrease the number of admissions as well as provide cost benefits and 
improvement of quality of life (Puhan et al., 2006,).  
 
6.3 Recommendations  
Based on the results of this study as well as the limitations identified in the research 
procedure the following recommendations are made:  
 
 Considering the increase in chronic diseases in the South African population access 
to reliable and valid information to assist in establishing the impact and burden of 
these diseases is needed and depends on accurate and legible documentation. 
This is an obvious requirement to maintain and document adequate information but 
is not being applied. In this study the information documented did not comply with 
the guidelines as published by SATS. The reasons for this could be due to either 
the guidelines not followed or that it was not documented.   
 Pulmonary rehabilitation programmes have been associated with decrease in 
admission of COPD patients with episodes of exacerbation. The fact that less than 
50% of this sample was admitted more than twice and some patients up to eight 
times leads to the question of the availability and utilization of pulmonary 
rehabilitation programmes.   
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 The economic impact of this disease on the South African workforce needs to be 
investigated as a large proportion of the study population were younger than 60 
years of age. Occupational air pollution also plays a role in the development of 
COPD. The impact of this combined with the other modifiable factors needs to be 
further investigated. This could potentially open an area for physiotherapists to 
assess the possibility of establishing a pulmonary rehabilitation program in the 
workplace. These programmes should be aimed at the younger COPD patient with 
mild disease as increasingly younger individuals are diagnosed with COPD and 
continue exposure to risk factors over a prolonged period of time will increase the 
severity of the disease.  
 Viral and bacterial infections as a cause of COPD acute exacerbation are well 
documented but in the South African context COPD patients that are 
immunocompromised due to HIV/AIDS and Tuberculosis may be at increase risk of 
hospital admission (www.who Tuberculosis.htm, accessed 14.08.2006). This is an 
aspect in the field of COPD that requires further investigation. Prospective studies 
specifically investigating the role of infections in the South African COPD patient 
presenting with acute exacerbation are needed. 
 A concerned identified in the current study was the need to establish the 
socioeconomic burden of COPD but due to the study design was not investigated. 
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Addendum A 
 
Patient Data Capture Sheet 
                       Patient code:  
 
Please tick () the appropriate box and fill in not applicable (n/a) if not relevant. 
                       Hospital: 
Panorama Medi-Clinic  
Louis Leipoldt Medi-Clinic  
Tygerberg  
Karl Bremer  
 
Reason for 
admission 
Bronchospasm Unspecified 
infection 
Increase in 
sputum 
production 
Deterioration 
in symptoms
 New 
arrhythmias 
Pneumonia Deterioration in 
mobility 
Dyspnoea 
 
Date of Birth   
Gender 
Male/female 
Employment 
status 
Employed  Unemployed  Pensi1r  Disability 
Grant 
Weight in kg   Height in cm  
Admission Date    
Vital Signs    Adm     D/C 
Discharge Date  Pulse   
ICU admission Yes/No Respiratory Rate   
Medical condition  Temperature   
Stroke  Blood pressure   
Cor Pulmonale  Oxygen 
Saturation
  
Congestive cardiac failure  Lung Function Admission 
Pulmonary embolism  FEVı  
Hypertension  FVC  
Ischaemic Heart Disease  FEVı/FVC  
Diabetes Mellitus  
Blood Gasses   
Cancer 
 
PaCO2   
Tuberculosis (TB)  PaO2   
Post TB bronchiectasis  pH  
Smoking? If yes, how many 
years? 
Yes/ No Walking with 
assistance: 
Yes /No 
Ex-smoker Yes /No O2 dependant in 
hospital  
Yes /No 
  Home O2 
Yes/No 
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Addendum B 
Readmission Capture Sheet      Patient code: 
Please tick () the appropriate box and fill in not applicable (n/a) if not relevant. 
                          Hospital:  
 
Panorama Medi-Clinic  
Louis Leipoldt Medi-Clinic  
Tygerberg  
Karl Bremer  
 
 
Admission Date    
Vital Signs    Adm    D/C 
Discharge Date  Pulse   
ICU admission Yes/No Respiratory Rate   
Reason for 
admission 
 Temperature   
Pneumonia  Blood pressure   
Dyspnoea     
Bronchospasm     
Unspecified infection     
Increase in sputum 
production 
 Lung Function   
Deterioration in 
respiratory symptoms 
 FEVı   
Deterioration in 
mobility 
 
FVC   
New Arrhythmias  
FEVı/FVC   
Medical condition  Blood Gasses   
Stroke  PaCO2  
Cor Pulmonale  PaO2  
Congestive cardiac 
failure 
 pH  
Pulmonary embolism  Oxygen 
Saturation 
 
Hypertension  Walking:           Yes /No 
Ischaemic Heart 
Disease 
 Walking with 
assistance 
Yes /No 
Diabetes Mellitus  
O2 dependant in 
hospital  
Yes /No 
Cancer  Home O2 Yes/No 
Tuberculosis (TB)    
Post TB 
bronchiectasis 
   
Smoking? If yes, 
how many years? 
Yes/ No Ex-smoker Yes/No 
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Addendum C 
 
Medication Data Capture Sheet 
 
Patient code: 
                                                  Please tick () the appropriate box  
                                       
                                                  Hospital: 
Panorama Medi-Clinic  
Louis Leipoldt Medi-Clinic  
Tygerberg  
Karl Bremer  
 
Indicate medication by individual name 
Date 
Bronchodilators  Theophylline/ 
Aminophylline 
  Cortico 
steriods  
Antibiotics Mucolytic 
Agents 
Other: 
HPT/ 
Cardiac 
meds 
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Addendum D 
                     Patient Confidentiality Data Capture Sheet 
 
Patient Name 
Medical File Number 
Patient Code 
1.  01 
2.  02 
3.  03 
4.  04 
5.  05 
6.  06 
7.  07 
8.  08 
9.  09 
10.  10 
11.  11 
12.  12 
13.  13 
14.  14 
15.  15 
16.  16 
17.  17 
18.  18 
19.  19 
20.  20 
21.  21 
22.  22 
23.  23 
24.  24 
25.  25 
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Addendum H 
Vocabulary  
 
AAT =alpha1 antitrypsin  
Adm= admission 
AIDS= acquired immune deficiency syndrome  
ATS= American Thoracic Society 
BCM=body cell mass 
BMI=body mass index 
Ca= cancer 
CCF=congestive cardiac failure 
COPD= Chronic Obstructive Pulmonary Disease.  
CRDQ= Chronic Respiratory Disease Questionnaire 
CRQ= Chronic Respiratory Questionnaire  
DALY =disability-adjusted life years  
D/C =discharge 
DM=diabetes mellitus 
ERS= European Respiratory Society 
FEV1 = forced expiratory volume in one second 
FFM=Fat Free Mass 
FVC= forced vital capacity 
GOLD=Global Initiative for Obstructive Lung Disease 
GBD= Global Burden of Disease study 
HIV= human immunodeficiency virus 
HRQOL= Health Related Quality Of Life 
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HPT= hypertension 
IHD= ischaemic heart disease 
LTOT= Long Term Oxygen Therapy 
LOS= length of stay 
NHLBI= National Heart Lung and Blood Institute 
O2 = Oxygen 
PaO2=Arterial pressure of oxygen 
PaCO2 =Arterial pressure of carbon dioxide 
PEFR= peak expiratory flow rate 
pH= relates to the acid/ base status of blood 
SATS= South African Thoracic Society 
SF-36= Short Form 36-item Questionnaire 
SGRQ= St George’s Respiratory Questionnaire 
SOLDQ= Seattle Obstructive Lung Disease Questionnaire 
SOB= Short of Breath 
TB=Tuberculosis 
WHO= The World Health Organisation 
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